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ABSTRACT OF THE DISSERTATION
The Effect of Procedural Pain on Purines, MDA and Allantoin in
Premature Infants
by
Megan Sue Holden
Doctor of Philosophy, Graduate Program in Biochemistry
Loma Linda University, June 2013
Dr. Penelope Duerksen-Hughes, Chairperson

Identifying and measuring the biochemical effects of procedural pain in infants is
a continuing challenge for clinicians. To address this issue we evaluated the relationship
between procedural pain, ATP utilization (hypoxanthine and uric acid), and oxidative
stress (MDA and allantoin) in premature infants. Through these studies we found that 1)
a single heel-lance significantly increases plasma uric acid in rabbit kits, 2) tape removal
increases MDA and prevents a decrease in uric acid in the plasma of premature infants,
and 3) a single dose of oral sucrose before a heel-lance is sufficient to significantly
increase plasma markers of ATP utilization and oxidative stress. These studies indicate
that, in premature infants, ATP utilization and oxidative stress are altered by procedural
pain and that oral sucrose, a common analgesia, may increase ATP breakdown.
Next, we examined clinical factors that need to be considered when using the
urinary concentrations of hypoxanthine, xanthine, uric acid, and allantoin to evaluate the
biochemical effects of procedural pain. Specifically, we determined the effects of
gestational age, weight for gestational age, and neonatal morbidity on the urinary
concentration of purines and allantoin. We found infants born at earlier gestational ages
had significantly higher urinary purine and allantoin concentrations compared to infants

xvi

born at later gestations, after 31 weeks. Weight for gestational age also altered the
urinary concentration of purines with small for gestational age infants having
significantly lower urinary hypoxanthine compared to appropriate and large for
gestational age infants. In addition, respiratory morbidity significantly increased urinary
purines, but not allantoin, within the late preterm population. These data suggest that
gestational age, weight for gestational age, and neonatal morbidity alter the urinary
concentration of purine metabolites. Allantoin was also found to be significantly altered
by gestational age. Based upon these data, we recommend conducting age-matched as
well as weight for age-matched studies when using urinary purines and allantoin to
evaluate the relationship between procedural pain and hypoxia on ATP utilization and
oxidative stress. Lastly, it is important to stratify subjects based on health status or
morbidity, due to the significant effects of respiratory diseases on ATP use and oxidative
stress.

xvii

CHAPTER ONE
INTRODUCTION

Infants Feel Pain
Before the 1980’s it was commonly believed that pain perception in neonates was
blunted or absent. Neonates were subjected to routine painful procedures and even
surgery with no anesthesia or analgesia. In 1987, however, Anand et al. reported that
even premature infants have the anatomical structures and functional requirements
necessary to perceive pain [1]. Further investigations on the development of pain
pathways revealed that, due to immature decending pain inhibition pathways, neonates
are likely to feel pain more intensely than adults and that this hypersensitivity is
exacerbated in premature neonates [2, 3].
In addition to feeling pain more intensely, infants who are exposed to repeated
painful stimuli are more likely to exhibit sighs of hyperalgesia, a prolonged and
exaggerated response to stimuli [3-6]. Research indicates that an insufficient release of
inhibitory neurotransmitters contributes to hyperalgesia in premature infants [3]. Tissue
injury can further promote hyperalgesia by stimulating an inflammatory response that,
because of nerve ending proliferation in the developing newborn, results in
hyperinnervation and increased pain perception [7-10].
It has also been suggested that infants can learn to anticipate pain. Goubet et al.
demonstrated that premature infants who had their leg held up for 10 seconds prior to a
heel stick showed significantly higher heart rate during leg lift on day five than on day

1

one [6]. Studies conducted by Taddio et al. reveled that full-term infants who were born
to diabetic mothers and were therefore exposed to repeated heel lances in the first 24 to
36 hours of life learned to anticipate pain [4]. This study also noted a heightened pain
response during venipuncture for infants who were born to diabetic mothers and exposed
to repeated heel lances. Taken together, these studies, in addition to several others,
clearly established that neonates perceive, feel, and may even remember or anticipate
pain [11-13]. Despite the knowledge that infants feel pain, developing effective
interventions and identifying the biochemical consequences pain in infants is a
continuing challenge for clinicians.

Painful Procedures In The NICU
Infants admitted to the neonatal intensive care unit (NICU) are repeatedly
subjected to noxious stimuli as part of their routine care. In 2003 it was reported that
infants in the NICU were exposed to roughly 14 ± 4 painful procedures per day and that
pharmacologic, as well as non-pharmacologic, analgesia was rarely used before an
invasive procedure [14]. This information was reaffirmed in 2008 when Carbajal et al.
reported that NICU patients were exposed to an average of 12 ± 8 painful procedures per
day and that many of these procedures were preformed without analgesia [15]. These
procedures included, but were not limited to: suctioning, heel-lance, tape removal, IV line
insertion/removal, intubation/extubation, lumbar puncture, and gastric tube insertion.
While these procedures are necessary, the metabolic and physiological consequences of
pain caused by these routine procedures in infants need to be examined further.
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In addition to examining the metabolic and physiological consequences of pain,
the efficacy of standard NICU pain management techniques needs to be examined. One
of the most common pain interventions for minimally invasive routine painful procedure
in the NICU is oral sucrose. Numerous studies report reductions in behavioral pain
scores when oral sucrose in administered prior to heel lance [16, 17]; however, recent
studies indicate that oral sucrose does not significantly reduce pain induced activity in
neonatal brain or spinal cord nociceptive circuits suggesting that oral sucrose may not be
effective at reducing pain [18]. The ability of oral sucrose to normalize the biochemical
changes that result from procedural pain needs to be examined.

Pain Response In Neonates
It is well documented that exposure to painful procedures can result in acute
metabolic and physiological changes like increased heart rate, tachycardia, decreased
oxygen saturation, decreased transcutaneous PaO2 (partial pressure of oxygen in arterial
blood), increased movement, altered somatosensory cortex hemodynamics, and increased
cortisol [19-25]. In addition to the immediate alterations in physiological state observed
to be associated with pain, research indicates that repeated painful procedures might have
long-term consequences. Brummelte et al. reported that greater neonatal procedural pain
may contribute to impaired brain development in premature infants [26]. Studies have
also reported higher pain response later in life in infants that were circumcised or exposed
to repeated painful procedures [27-29]. While research supports the idea that pain during
the neonatal period results in immediate and long term changes, little is known about the
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effects of procedural pain on adenosine triphosphate utilization (ATP) and oxidative
stress.

A Theoretical Link Between Pain And Atp Depletion
As described previously, common responses to painful procedures in neonates
often involve increased heart rate and decreased oxygen availability. Theoretically, this
combination of events could result in a hypoxic-like state where ATP utilization
surpasses ATP production and purine degradation products are formed. Research
indicates that increased heart rate can significantly increase ATP utilization [30].
Because the main source of ATP is oxidative phosphorylation, increased cardiac ATP
utilization is associated with increased myocardial oxygen consumption [31]. In order to
accommodate for the increase in oxygen demand, cardiac output increases to ensure
adequate oxygen delivery to the working tissues [32]. If oxygen consumption is not
matched by oxygen delivery, cellular hypoxia can occur. In premature infants,
tachycardia has the potential to decrease cardiac output by degreasing stroke volume [32,
33]. Specifically, tachycardia decreases stroke volume by limiting the time available for
ventricular filling during diastole. In addition, reductions in oxygen saturation are often
seen in infants experiencing pain. This combination of events has the potential to create a
hypoxic-like state where ATP production cannot match ATP utilization. This would be
reflected in plasma and urine by increased purine production.
In addition to variations in heart rate, hypoxemia also has the potential to reduce
ATP production. In patients with sleep apnea, plasma uric acid levels positively correlate
with the number of obstructive respiratory episodes and oxygen desaturations during
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sleep [34]. Furthermore, hypoxemia was shown to significantly decrease ATP and
increase inosine monophosphate in isolated rat hearts without significantly altering
phosphocreatine [35]. This study shows a relationship between hypoxemia and ATP
breakdown; however, plasma levels of ATP breakdown products were not evaluated. In
infants, it was shown that a significant inverse relationship exists between PaO2 and uric
acid (serum and urine) [36]. Taken together, these studies indicate that reductions on
oxygen saturation have the potential to alter the production of purine nucleotides;
however, the effects of transient decreases in oxygen saturation on purine production are
unknown.

The Purpose Of These Studies
Based upon the physiological responses observed to be associated with procedural
pain, we hypothesized that markers of hypoxia, a condition associated with ATP
depletion, could be used to evaluate the biochemical effects of procedural pain on ATP
utilization and oxidative stress in premature infants. We began our studies by reviewing
literature on well-established markers of hypoxia in order to determine which ones would
be best for evaluating ATP utilization and oxidative stress in small volumes of plasma
and urine (Chapter 2). Next we determined the most efficient means of quantifying the
chosen markers (Chapter 3). Then we determined the effect of acute pain on hypoxia
associated plasma markers of ATP catabolism (purines) and oxidative stress (MDA,
allantoin) in premature infants. To accomplish this we first developed an animal model
to measure the effect of a single heel-lance on plasma uric acid concentrations (Chapter
4). An animal model was chosen to control for the NICU environment and to enable the

5

researchers to measure the direct effect of a heel lance on plasma uric acid. Then we
measured the changes in plasma uric acid and MDA in premature infants exposed to a
common painful NICU procedure, tape removal (Chapter 5). Finally, we used our
markers to evaluate the efficacy of a commonly used intervention, oral sucrose (SweetEase), on relieving pain caused by a single heel lance (Chapter 6). These studies
revealed that 1) biochemical markers of hypoxia can be used to evaluate the effects of
acute pain on ATP catabolism and oxidative stress, 2) even acute pain can cause
significant changes in these markers, and 3) markers of ATP catabolism and oxidative
stress may be useful in evaluating the efficacy of analgesia.
In the next set of studies we evaluated the clinical factors that may affect the
utility of these compounds as urinary markers of pain (Chapter 7). Specifically, we
determined the effect of gestational age, weight for gestational age, and common neonatal
morbidities on the urinary concentrations of purines and allantoin in premature infants.
Late preterm infants were chosen to evaluate the effects of morbidity for several reasons.
First, this population is less likely to have central catheter lines when compared to more
premature infants. Second, research has already established the effects of morbidity on
purine concentrations in infants with younger gestational ages; however, the effect of
both mild and severe forms of morbidity on the urinary concentrations of purines and
allantoin on late preterm infants is unknown. Third, the late preterm population is
understudied and often clinically managed as if they were term. Lastly, we hypothesized
that the urinary excretion of purine and allantoin would be inversely related to gestation
and wanted to control for this in our morbidity studies. These studies revealed that
gestational age, weight for gestational age, and neonatal morbidity alter the urinary
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excretion of purine and allantoin and need to be accounted for when using these
compounds to evaluate the metabolic consequences of pain in premature infants.
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Abstract
Neonatal hypoxia is a clinical condition with detrimental biochemical and clinical
outcomes including production of reactive oxygen and nitrogen species, ATP depletion,
developmental abnormalities and growth retardation. Diagnostic approaches for hypoxia
are largely based on nonspecific clinical criteria such as Apgar score, umbilical cord pH,
and fetal heart rate monitoring. Since our understanding of the biochemical processes of
hypoxia has improved, several biochemical markers have been developed. This review
highlights the use of hypoxanthine, xanthine, uric acid, xanthine oxidase,
malondialdehyde (MDA), nitrotyrosine and lactate as markers of hypoxia in animal
models, preterm neonates, and full-term neonates.
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Background
Hypoxemia refers to low oxygen concentration in the arterial blood, while
hypoxia suggests inadequate oxygen availability to the tissues. Hypoxia frequently
occurs in the neonatal intensive care unit (NICU) and is a consequence of neonatal
diseases, such respiratory distress syndrome, persistent pulmonary hypertension of the
newborn, apnea of prematurity, bronchopulmonary dysplasia, hemorrhagic diseases and
congenital heart disease. Respiratory distress that result in hypoxia occur in 10% of term
newborn [1]. This incidence increases as gestational age decreases [2]. Upon admission
to the NICU, infants are handled up to 110 times/day [3]. Of these handling episodes,
75% result in oxygen desaturation [4]. Owing to the lack of reliable methods to quantify
hypoxia at the bedside, it is not known if these hypoxemic events result in cellular
hypoxia. Hypoxia may be the result of:


Low PO2 of the inspired air or poorly oxygenated lungs



Decreased hemoglobin



Deficiencies in oxygen transport and/or utilization

Alveolar hypoxia represents the condition of reduced alveolar PO2, often owing to
some restriction in gas exchange. This can elicit a compensatory vasoconstriction of the
arterial vessels leading to the affected alveoli, thus minimizing the perfusion of underoxygenated alveoli. Hypoxemic hypoxia is the form of hypoxia that is caused by
hypoxemia despite adequate tissue perfusion. Sometimes also referred to as hypoxic
hypoxia, this condition arises as a result of a reduction in the delivery of oxygen to the
pulmonary capillary system, ultimately leading to low intracellular oxygen
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concentrations. This represents the most common form of hypoxic insult in neonates and
tends to exacerbate numerous diseases, abnormalities and developmental problems [5-8].
Furthermore, neonatal hypoxia is associated with a high morbidity and mortality rate. In
order to identify a condition that can have its effects anywhere in the body, it is important
that the condition be categorized according to its biochemical effects on the body.
The detrimental biochemical consequences of hypoxia are due to the processes that occur
during anaerobic metabolism (Figure 1). In times of oxidative stress, metabolism is
forced to switch from aerobic to anaerobic and steady-state concentrations of ATP will
decrease [9]. The decrease in ATP is due to a lack of oxidative phosphorylation coupled
with continued utilization of ATP for energy. One of the many functions of oxidative
phosphorylation is to generate a proton gradient to drive the enzyme, ATP synthase, to
synthesize ATP from ADP and inorganic phosphate [10, 11]. Since oxygen is required
for oxidative phosphorylation to generate the proton gradient that drives ATP synthase,
insufficient amounts of oxygen results in reduced or halted ATP production. The
combination of inhibited ATP production and lack of oxygen puts the body in an energydeprived state. To compensate for this, molecules containing high-energy phosphate
bonds, such as ATP, are broken down in order to provide energy for normal cellular
processes [9]. Furthermore, the body will switch to anaerobic metabolism, converting
pyruvate to lactate in order to re-generate NAD+, enabling glycolysis to continue
producing ATP (Figure 2). However, the resulting ATP is rapidly consumed. Thus,
even with continued ATP production via anaerobic glycolysis, there is a steady decrease
in cellular energy levels accompanied by increased release of free adenosine. The free
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Figure 1: Formation of the Biochemical markers of hypoxia. NMDA: N-methyl-D-aspartate;
MDA: Malondialdehyde; NOS: Nitric Oxide Synthase; Pi: Inorganic Phosphate; ROS: Reactive
Oxygen Species.
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Figure 2: Cori Cycle. During anaerobic metabolism, pyruvate is converted into lactate to
regenerate NAD+ in order to enable glycolysis to continue.
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adenosine will be degraded to inosine, hypoxanthine, xanthine, and finally to uric acid.
The latter two steps are catalyzed by xanthine oxidoreductase, a molybdopyranopterincontaining enzyme, that may be present in two distinct functional forms, xanthine
dehydrogenase or xanthine oxidase [12, 13]. Under normoxic conditions, the enzyme
form responsible for the degradation of hypoxanthine to xanthine and xanthine to uric
acid is xanthine dehydrogenase [14]. Xanthine dehydrogenase is dependent on NAD+,
one of the major byproducts of oxidative phosphorylation [15]. Anaerobic glycolysis
during hypoxia leads to increased consumption of NAD+, while reduced oxidative
phosphorylation effectively decreases NAD+ production. Together these processes result
in reduced levels of NAD+. Under these hypoxic conditions, xanthine dehydrogenase is
converted into xanthine oxidase [16]. Xanthine oxidase is activated during reperfusion
and performs the same purine degradation steps as xanthine dehydrogenase, with the
exception that xanthine oxidase uses oxygen instead of NAD+ as an oxidant [16]. A side
effect of this reliance on oxygen is the production of reactive oxygen species (ROS), such
as superoxide and hydrogen peroxide, as well as reactive nitrogen species (RNS), such as
peroxynitrite. In addition to the conversion of xanthine dehydrogenase into xanthine
oxidase, reduced levels of NAD+ also lead to the inhibition of the citric acid cycle,
shifting pyruvate conversion to lactate, accompanied by a temporary compensatory
NAD+ return [17].
In the brain, hypoxia-induced membrane depolarization triggers an increase in
intracellular calcium, facilitated by a glutamate-induced increase in NMDA receptors
[18-20]. High intracellular calcium levels also contribute to the conversion of xanthine
dehydrogenase to xanthine oxidase, and the subsequent production of ROS and RNS [9,
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21]. These proposed mechanisms are reinforced by data that demonstrate that the
metabolic changes induced by hypoxia result in an increase in the concentration of ROS
[22-24]. The major producer of ROS during hypoxia is xanthine oxidase, but it has been
proposed that the mitochondria, nicotinamide adenine dinucleotide phosphate oxidase
and free fatty acids may also contribute to the generation of ROS [21, 25-27]. Owing to
the numerous biochemical changes that occur as a result of the hypoxia-induced
transition from aerobic to anaerobic metabolism, there are a growing number of potential
biochemical markers that may be useful for quantitative clinical evaluation of the severity
of sustained hypoxic stress or trauma. This review will not discuss hypoxia markers
detected by medical imaging or UV-Vis spectroscopy.

Clinical Markers Of Hypoxia
The currently accepted method of diagnosing fetal/perinatal hypoxia involves a
combination of nonspecific indicators: Apgar score, umbilical cord pH, Sarnat staging,
and fetal heart rate monitoring. The Apgar score evaluates five elements, each on a scale
of 0-2, at 1 and 5 minutes after birth. These five elements are heart rate, respiratory
effort, muscle tone, reflex irritability, and color [28]. However, it has been demonstrated
that several obstetric risk factors other than hypoxia are associated with a low 5-min
Apgar score in term infants and that the Apgar score has low interobserver reliability [2830]. Therefore, while this method may provide a general diagnosis of physiologic stress,
it does not correlate well with the severity of the hypoxic insult. Furthermore, several
authors have shown the limited utility of the Apgar score in preterm infants [31, 32].
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Fetal heart rate monitoring is utilized widely for the assessment of fetal wellbeing,
but it can result in false-positive diagnosis of fetal asphyxia [33]. Another tool utilized
clinically is Sarnat staging, a method for defining the stages of encephalopathy in
asphyxiated neonates, without electroencephalography. This method demonstrates a
good correlation between stages of encephalopathy and outcome, but without adequate
predictive value for survival [34-36]. Furthermore, the inability to define clear stages of
encephalopathy in preterm infants greatly reduces the usefulness of Sarnat staging for this
vulnerable age group [37]. For all of these reasons, a combination of methods is used to
diagnose hypoxia. Even with a combination of diagnostic methods, the level of hypoxia
experienced by a neonate can be difficult to evaluate because it ranges from minor to
severe and its effects can present in the form of a wide array of symptoms.
Several factors, from the mother as well as the fetus, can contribute to the risks of
perinatal hypoxic stress. Chronic hypertension, infection, chronic substance abuse, preexisting diabetes mellitus, intrauterine growth restriction and pre-eclampsia are some of
the maternal factors that have been linked to neonatal hypoxia [38-41]. Other factors
include prolapsed umbilical cord, prolonged labor, nuchal cord, and placental abruption
[42-44]. With such a vast range of possible etiologies, it is not surprising that studies
have shown this condition to be the third leading cause of infant mortality in low risk
women in the United States [45]. Among surviving neonates, severity of hypoxia is
thought to correlate with neurological development and overall growth. Hypoxia has
been linked to developmental malformations in the brain, heart, stomach, liver, and other
organs [46-48]. Despite the fact that hypoxia is a major contributor to neonatal mortality
by direct or indirect means, diagnostic methods remain generally qualitative and
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nonspecific [49]. In order to successfully identify and measure the severity of neonatal
hypoxia, reliable quantifiable biochemical markers need to be evaluated for
implementation in the clinical setting.

Biochemical Markers
There are several biochemical markers of hypoxia that are currently being
evaluated to aid in the clinical diagnosis of hypoxia. The ultimate goal of these
biochemical markers is not only to quantify hypoxia, but also to predict the severity of
hypoxic insult. This would allow immediate identification and treatment of high-risk
neonates. Some of the most promising candidate markers for quantification of the
severity of hypoxia and prediction of its sequelae are purine degradation products, ROS
and lactate levels.

Detecting Hypoxia Using Purine Biochemical Markers
Purine metabolites were linked to hypoxia as early as 1963 when Berne observed
elevated levels of inosine and hypoxanthine in the myocardium of cats and dogs exposed
to hypoxia [50]. Since then, a number of studies evaluated the usefulness of purine
metabolites from urine, serum, cerebrospinal fluid (CSF) or other tissues in animal
models as well as humans. Several studies demonstrated the reliability of purines as
biochemical markers for the detection of hypoxia in neonates, children and adults [5155]. Furthermore, the enzyme responsible for the final two degradation steps of purine
metabolism, xanthine oxidase, is also being evaluated as a potential biochemical marker
for hypoxia. Since xanthine oxidase is the predominant form of xanthine oxidoreductase
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under conditions of hypoxia-reperfusion, as opposed to xanthine dehydrogenase which is
present under normoxic conditions, it has the potential to be a useful biochemical marker
of hypoxia.

Purine Metabolites In Animal Models
Several studies of hypoxia in mammals including sheep, rats, pigs, and rabbits
have demonstrated elevated levels hypoxanthine, xanthine, and uric acid in response to
oxidative stress (Table 1). It was shown in the fetal sheep that, during times of severe
hypoxia, the concentration of hypoxanthine in the CSF increases [56]. This same study
also demonstrated that serum hypoxanthine and xanthine in the fetal sheep increased in
response to mild and severe hypoxia [56]. In the adult rat, increased serum levels of uric
acid were reported as early as 24 h after a hypoxic insult [57]. In the pig and piglet
models, hypoxia-induced rises in purine degradation products were observed in serum,
urine, and CSF samples [58]. Further work with pigs and piglets also demonstrated
increased hypoxanthine, xanthine, and uric acid in response to hypoxia in the vitreous
humor [59]. These animal models demonstrate that purine metabolites may serve as
useful biochemical markers of hypoxia in a number of mammals, and further efforts to
study the relationship between the severity of hypoxia and these biochemical markers are
needed. Physiological relevance could be strengthened by examination of correlation of
purine metabolites with brain white matter injury in the various animal models. Previous
studies demonstrated that many neurodevelopmental aspects of nonhuman mammals
parallel human brain development, and that the brain development of some animal
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Table 1: Biochemical markers of Hypoxia in Animals. CSF: cerebrospinal fluid; 1H-NMR:
proton nuclear magnetic resonance; MDA: Malondialdehyde
Biochemical
marker
Hypoxanthine

Species
Fetal
Sheep

Method Of
Measurement
1
H-NMR [65]

Condition Of
Animal
Severe
Hypoxia
Normoxic

Pig

HPLC[66, 67]

Hypoxemic

Normoxic

Xanthine

Fetal
Sheep

Pig

1

H-NMR [65]

Severe
Hypoxia
Normoxic

HPLC[66, 67]

Hypoxemic

Normoxic

Uric Acid

Rat

Pig

MDA

Nitrotyrosine

Piglet

Rat Pup

Rat

Recorded
Level
53 μmol/L
58.1±25.6
μmol/L
14.3±11.3
μmol/L

Ref.

CSF
Serum
Urine
CSF
Serum
Urine

39.9 μmol/L
103.6 μmol/L
87.1 μmol/L
18.1 μmol/L
25.4 μmol/L
21.3 μmol/L

[58]

Arterial
Blood
Arterial
Blood
CSF
Serum
Urine
CSF
Serum
Urine

12.1±6.5
μmol/L
4.1±0.8
μmol/L
10.6 μmol/L
48.1 μmol/L
12.6 μmol/L
4.0 μmol/L
0.7 μmol/L
4.0 μmol/L

[56]

[57]

[69]

[56]

[58]

Modified
Phosphotungstate Method[68]

Hypoxic

Serum

Normoxic

Serum

HPLC[66, 67]

Hypoxemic

CSF
Serum
CSF
Serum

3.21±1.0
mg/dL
0.98±1.0
mg/dL
16.3 μmol/L
208 μmol/L
3.1 μmol/L
15.3 μmol/L

Hypoxic

Plasma

4-18 μU/ml

Normoxic

Plasma

Undetectable

Hypoxic

Intestinal
Tissue

[72]

Normoxic

Intestinal
Tissue

3.826±0.425
nmol/mg
protein
2.164±0.229
nmol/mg
protein

Hypoxic

Striatum
Supernatant

133.5±16.8%

[73]

Normoxic

Striatum
Supernatant

104.3±10.0%

Normoxic
Xanthine
Oxidase

Source Of
Sample
CSF
Arterial
Blood
Arterial
Blood

Radioactivity
Of Uric Acid
From The
Conversion of
C14-Xanthine
Methods
Developed By
Ohkawa et a1
[70]
& Lowry et al
[71]
Optical Density
Of Western
Blot Bands
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[58]

models at full- term coincide with brain development of preterm human neonates [60].
This supports the use of animal models to evaluate the extent of brain damage as a result
hypoxic insult.
Several animal models were employed to examine the relationship between
hypoxia and the expression of xanthine oxidase activity. These include piglets, rats, and
Chinese hamsters. In 1995, increased circulation levels of xanthine oxidase were
reported, from non- measurable to detectable, in five of 19 piglets, after experimental
ischemia followed by reoxygenation (Table 1) [61]. However, this study also indicated
that the xanthine oxidase levels did not correlate with documented brain damage [61]. In
a rat liver and cultured liver cells, xanthine oxidase activity was shown to have a positive
correlation with duration and severity of hypoxia [62, 63]. Increased xanthine oxidase
activity was also observed in Chinese hamster V79 cells, which were exposed to hypoxia
followed by reoxygenation [64]. These animal models demonstrate that purine
biochemical markers of hypoxia are not limited to one species, and efforts to correlate the
brain injury with the biochemical markers of hypoxia found in serum, urine, and CSF
should be further evaluated.

Purine Metabolites In Hypoxic Full-Term Neonates
Increased purine degradation products were demonstrated in full-term neonates that
experienced periods of hypoxia (Table 2). In 1982 Harkness et al. reported a
noninvasive way to measure hypoxanthine and xanthine in the urine of full-term neonates
[53]. It was demonstrated that hypoxanthine and xanthine levels were higher in neonates
following an apneic attack and that the severity of neurological damage correlated with
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excreted hypoxanthine and xanthine [53]. Increased hypoxanthine and xanthine were
also documented in serum of asphyxiated full-term infants [74]. In addition, full-term
neonates were reported to have elevated hypoxanthine, xanthine and uric acid in CSF as a
result of hypoxia [54]. In this latter report, hypoxanthine was the better indicator of brain
damage [54]. Additional studies have also demonstrated elevated levels of serum
hypoxanthine in 48% of full-term, hypoxic neonates [75]. There are few data to
substantiate xanthine as a helpful biochemical marker of hypoxia in full-term neonates,
but this may be due to relatively low concentration of xanthine compared to
hypoxanthine or uric acid [76]. Elevated urine or serum uric acid concentrations were
observed in hypoxic full-term neonates on day one of life and, to a lesser extent, on day 3
of life [77]. Uric acid:creatinine ratio was proposed as a reliable biochemical marker for
the diagnosis of perinatal asphyxia and for the determination of the stage of hypoxic
ischemic encephalopathy [78]. Despite the correlation between increased uric acid and
hypoxia, some studies indicated that uric acid may not be as useful in predicting the
severity of the resultant brain injury, based on observations that mean uric acid levels do
not significantly differ between infants with and without severe brain injury or between
those with severe, moderate or mild hypoxic ischemic encephalopathy [89, 90].
Nevertheless, hypoxanthine or xanthine measurements in serum or plasma show promise
in predicting the amount of injury caused by hypoxic insult.
The role of xanthine oxidase in the hypoxic full-term neonate is unclear because
well-conducted studies that report measurements of this enzyme are still lacking.
However, there are some reports of functional xanthine oxidase measurements in adults
and in neonates with sepsis, clearly under stressful conditions (Table 2). Increased
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Table 2. Biochemical markers of Hypoxia in Full Term Neonates. CSF: cerebrospinal fluid;
GCMS: Gas Chromatography Mass Spectrometry
Biochemical Marker

Method Of
Measurement

Condition Of
Patient

Source Of
Sample

Recorded
Level

Ref.

Hypoxanthine

HPLC[79]

Hypoxic

CSF

25.3 μmol/L

[80]

Normoxic

CSF

1.8-5.5 μmol/L

Hypoxic

CSF

35.8 μmol/L

Normoxic

CSF

0.9-9.1 μmol/L

Hypoxic

CSF

70 μmol/L

Normoxic

CSF

30±25 μmol/L

Auto-analyzer
Hitachi 747
Uricase
Enzymatic
Kinetic
Method

Mild
Hypoxia
Moderate
Hypoxia

Urine

0.95±0.55
Uric Acid/Cr
2.16±0.34
Uric Acid/Cr

Severe
Hypoxia

Urine

3.33±0.73
Uric Acid/Cr

Horecker &
Heppel’s
Method[82]

Septic

Serum

5.27 (2.07)
μmol/min/ml

Control

Serum

3.43 (1.27)
μmol/min/ml
9.5 (1.6)
μmol/hr/dl
7.0 (0.78)
μmol/hr/dl

Xanthine

Uric Acid

Xanthine Oxidase

MDA

Nitrotyrosine

Nitrotyrosine metabolites

HPLC[79]

HPLC[79]

Urine

Seethambaram
& Das’ s
Method[84]

Septic

Serum

Control

Serum

Thiobarbituric
Acid
Reaction[85]

Delivery
Room
Resuscitation

Serum

6.96±8 1.12
μmol/L

Urine

4.67±8 1.50
μmol/L

Control

Serum

5.26±8 0.63
μmol/L

Urine

2.45±8 0.56
μmol/L

Thalamus

70%

Olives

68%

Cerebellu
m
Pons

33%

Immunohistoc
hemical
Staining

GCMS

Asphyxiated

Normoxic

3-nitro-4-hydroxyphenylacetic acid (NHPA)
para-hydroxyphenyl-acetic
acid (PHPA)

[80]

[81]

[83]

[83]

[86]

[87]

29%

Urine

[88]
31.47± 7.27
ng/ml
2.12±0.79
mg/ml
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[80]

xanthine oxidase activity was reported in neonates with sepsis, but this study sampled
patients irrespective of gestational age and specifically excluded asphyxiated infants [91].
Elevated plasma xanthine oxidase activity was also reported in adults with acute
respiratory distress syndrome [92]. Higher levels of xanthine oxidase in both maternal
and fetal plasma were reported in pregnancies complicated by pre-eclampsia [93]. Much
more work is needed before xanthine oxidase can considered as a potential biochemical
marker of hypoxia in full-term neonates.

Purine Metabolites In Preterm Neonates
Purine metabolites, measured in urine or serum, were proposed to be helpful
biomarkers of hypoxia in preterm neonates. Urinary uric acid and xanthine, but not
hypoxanthine, were reported to be significantly elevated in the hypoxic neonates on day 1
and 2 of life when compared to normoxic neonates [76]. More recently, however, it was
demonstrated that serum hypoxanthine levels were increased in hypoxic preterm infants
at birth and continued to be elevated until 7 day of life (Table 3)[94]. Buonocore et al.
further substantiated the reliability of purine degradation products as biochemical
markers of hypoxia in preterm neonates, reporting increased serum levels of
hypoxanthine, xanthine and uric acid (Table 3) [102]. Subsequently, a correlation was
documented between serum levels of xanthine or hypoxanthine and periventricularintraventricular hemorrhage, a condition that affects 15-20% of preterm infants[103]. A
group of investigators also suggested the use of xanthine oxidase as a biochemical marker
of hypoxia in the preterm neonates. A study involving normoxic and hypoxic preterm
infants demonstrated that the xanthine oxidase activity in arterial blood was elevated 4 h
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Table 3. Values of biochemical markers of hypoxia in preterm neonates. ABST: 2,2’-azinobis(3-ethylbenzthioazoline-6-sulphonic acid); GCMS: Gas Chromatography Mass Spectrometry.

after birth in the hypoxic poor outcome group when compared with control groups [104].
Biochemical
Marker

Method Of
Measurement

Condition Of
Patient

Source Of
Sample

Recorded
Level

Ref.

Hypoxanthine

HPLC

Hypoxic

Cord Blood

[95]

Normoxic

Cord Blood

Hypoxic

Plasma

Normoxic

Plasma

Hypoxic

Plasma

Normoxic

Plasma

Hypoxic

Plasma

Normoxic

Plasma

Hypoxic

Plasma

3.9 ± 2.5
μg/ml
1.6 ± 1.4
μg/ml
3.89± 0.46
μg/ml
1.13± 0.16
μg/ml
1.16± 0.2
μg/ml
0.56± 1.71
μg/ml
51.77± 4.01
μg/ml
21.69± 3.3
μg/ml
4.7±0.6
mU/ml

Normoxic

Plasma

1.1±0.2
mU/ml

Hypoxic

Plasma

[83,
99]

Hypoxic

Plasma

0.52±0.20
nmol/ml
9.19 (1.28)
μmol/hr/dl

Developed
Bronchopulmonary
Dysplasia

Plasma

0.05-1.3
ng/mg protein

[101]

Did Not Develop
Bronchopulmonary
Dysplasia

Plasma

Non
Detectable–
0.25 ng/mg
protein

Normoxic

Urine

HPLC

Xanthine

Uric Acid

Xanthine Oxidase

MDA

Nitrotyrosine

Nitrotyrosine
Metabolites

HPLC

HPLC

Spectrophotometric Monitoring
& Conversion of
Hypoxanthine To
Urate &
Oxidation Of The
Chromogren
ABTS
HPLC[98]
Seethambaram &
Das’ s
Method[84]
Solid-phase,
Antibody-Capture
Immunoradiochemical
Assay[100]

GCMS

[96]

[96]

[97]

[88]

3-nitro-4hydroxyphenylacetic acid (NHPA)

14.58± 4.49
ng/ml

parahydroxyphenylacetic acid (PHPA)

0.99±0.38
mg/ml
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[96]

As was the case with full-term infants, there is little data on the levels of xanthine oxidase
in the preterm neonates, but the information gained thus far suggests that xanthine
oxidase may be an important marker of hypoxia.

Detecting Hypoxia Using ROS & RNS Biochemical Markers
Products of short-lived ROS or RNS, specifically malondialdehyde (MDA) and
nitrotyrosine (Figure 1) may also serve as biochemical markers of hypoxic stress. MDA
is a thiobarbituric acid–reacting substance that is formed by the action of ROS on lipid
membranes [49, 105, 106]. Because hypoxia and reoxygenation was shown to generate
ROS, and MDA measurement is a commonly used indicator of oxygen induced radical
damage [105, 107], it was proposed that MDA could be used as a biochemical marker of
hypoxia reoxygenation and may even correlate with the severity of cellular or tissue
damage and outcome. Other lipid peroxidase products, such as lipid hydroperoxides,
have been shown to increase in response to acute cerebral ischemia complicated by
hypoxia and reperfusion, but MDA was shown to increase by a greater percentage than
lipid hydroperoxides [108]. Nitrotyrosine is generally formed by the reaction of
peroxynitrite with free or bound tyrosine residues, but can also be formed as a byproduct
of myeloperoxidase released from neutrophils during an inflammatory response [109].
Nitric oxide can react with a suitable ROS, such as superoxide anions (O2∙−), to form
peroxynitrite [110, 111]. However, nitric oxide formation is dependent on nitric oxide
synthase, an enzyme that is induced during the inflammatory response [109] and
activated by elevated intracellular calcium levels [21]. In adults, investigators showed
that CSF nitrotyrosine levels can be used as a reliable predictor of poor neurological
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outcomes, making nitrotyrosine of key interest in correlating severity of hypoxia damage
with outcome [112].

ROS & RNS In Animal Models
Several animal studies using mouse, rat or goat models, demonstrated the
reliability of MDA as a marker of hypoxia and reoxygenation. Representative reported
values of MDA levels are presented in Table 1. In the adult mouse model, it was shown
that severe, chronic intermittent hypoxia results in a 60% increase in liver MDA while
moderate, chronic intermittent hypoxia results in a 25% increase in liver MDA levels
[113]. These data indicate that MDA may be helpful in determining the severity of
hypoxia. A study on necrotizing enterocolitis showed that rat pups exposed to hypoxia
and reoxygenation exhibited significantly elevated intestinal tissue MDA in comparison
to rat pups exposed to normoxic conditions [6]. MDA levels in other tissues as well as
body fluids were also studied. Elevated serum levels were observed in rats exposed to
hypoxia and reoxygenation [114]. Similarly, elevated plasma levels of MDA were
observed in fetal goats subjected to cord occlusion [115].
Although several studies demonstrate the usefulness of MDA as an indicator of
hypoxia, there are some factors that need to be taken into consideration when utilizing
MDA as a biochemical marker of hypoxia and reoxygenation. A study by Yamada et al.
reported that fetal plasma MDA levels were significantly elevated after the initiation of
maternal oxygen supplementation [115]. Furthermore, Loiseaux-Meunier et al.
demonstrated elevated levels of MDA in adults that received hyperoxia oxygen therapy
[116]. This suggest that oxygen supplementation in the absence of hypoxia can also
increase plasma MDA levels.
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The effects of hypoxia on nitrotyrosine levels were also studied in several animal
models including rabbit and rat (Table 1). Western blot, immunohistochemical, and
HPLC techniques were commonly employed to demonstrate elevated production of
nitrotyrosine after hypoxic exposure. A group of investigators, employing HPLC with
electrochemical detection, found increased nitrotyrosine formation from protein bound
tyrosine in brain tissue of fetal rabbits following repetitive uterine ischemia-reperfusion
[117]. Nitrotyrosine quantitation was further substantiated by the observation that
nitrotyrosine levels were reduced following the administration of a selective neuronal
nitric oxide synthase inhibitor to fetus [117]. Similarly, nitrotyrosine formation was
evaluated immunohistochemically and by Western blotting in striatal samples from rats
exposed to hypobaric hypoxia. Increased nitrotyrosine levels accompanied increased
levels of neuronal, constitutive and endothelial nitric oxide synthase in rat caudate
putamen [118]. Since nitrotyrosine is elevated under conditions of oxidative stress and
since it is also a known mediator of myeloperoxidase, an enzyme present under
inflammatory conditions [108], it may be helpful to use nitrotyrosine as a marker of
hypoxia induced inflammation cell damage. Elevated nitrotyrosine was colocalized in
the brains of hypoxic rats with several indicators of cellular injury, including a loss of
microtubule-associated protein-2, presence of active caspase-3, nuclear translocation of
apoptosis-inducing factor and evidence of specific DNA strand breaks [119].
Colocalization of nitrotyrosine with markers of cell damage strengthens its potential
utilization as a clinical indicator of brain damage that occurs after hypoxia.

30

ROS & RNS Markers In Full-Term Neonates
Biochemical markers of ROS and RNS were employed in several studies as
indicators of hypoxia in neonates (Table 2). Kumar et al. compared serum and urinary
concentrations of MDA between full-term neonates that received delivery-room
resuscitation and a healthy group of control neonates [120]. They observed elevated
levels of serum and urinary MDA in delivery room resuscitated neonates, and noted that
infants with clear signs of fetal and neonatal distress (meconium staining, hypoxic
ischemic encephalopathy or death), exhibited the highest levels of MDA [120]. Similar
increases in MDA levels, as a result of hypoxia, were also demonstrated in the plasma of
blood samples taken from placental part of the umbilical cord [121]. While some data
regarding urinary and serum levels of MDA are available for hypoxic and normoxic
neonates, little is known regarding the MDA levels in the CSF. More studies using MDA
measurements are required to definitively characterize lipid peroxidation due to oxidative
stress in neonates. Furthermore, there is evidence that factors other than hypoxia can
affect the levels of MDA. Kahw et al. recorded significantly elevated levels of plasma
MDA in umbilical cord and maternal blood samples after the administration of maternal
oxygen supplementation [122]. It has also been observed that small-for-gestational-age
term infants, born to undernourished mothers, had higher serum MDA levels than
average for gestational age infants born to healthy mothers[123]. More studies are
required to characterize factors that alter MDA in biologic fluids and as a potential
marker of cellular damage induced by oxidative stress.
Elevated nitrotyrosine was documented in human neonatal brain (Table 2). A
study of 22 full-term asphyxiated neonates demonstrated increased nitrotyrosine staining
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in brain tissue samples [124]. Nitrotyrosine was also found in the spinal cord of
asphyxiated full-term neonates. A study of 18 asphyxiated neonates demonstrated
positive nitrotyrosine staining in five, with the highest nitrotyrosine staining in an infant
who died shortly after the hypoxic-ischemic insult [125]. Further work is needed to
obtain information regarding nitrotyrosine levels in CSF, serum, and urine of full-term
infants with or without hypoxia.

ROS & RNS Markers In Preterm Neonates
Malondialdehyde levels were measured in preterm neonates in several reports.
Serum MDA levels were found to be markedly higher in hypoxic preterm neonates in
umbilical cord blood as well as blood samples on day 4 of life when compared to hypoxic
term neonates [99]. Elevated urinary MDA was reported in infants with
bronchopulmonary dysplasia [126]. It has also been observed that the MDA was
inversely related to birthweight [126]. Urinary MDA measurements gained legitimacy
when it was reported that plasma changes in MDA are followed by changes in urinary
MDA 24 h later [127]. Increased levels of MDA have been observed in infants born to
mothers who went through labor as opposed to those who had elective caesarean section
without labor [128].
Studies measuring nitrotyrosine in hypoxic preterm infants are rare (Table 3).
Plasma nitrotyrosine was found to be significantly higher in preterm neonates with
bronchopulmonary dysplasia [129]. Furthermore, Hoehn et al. demonstrated that certain
degradation products of nitrotyrosine can also be quantified in the urine of preterm
normoxic infants [130]. Thus, it appears that nitrotyrosine can be measured in serum and
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urine of preterm neonates. Additional studies are needed to measure nitrotyrosine in
hypoxic neonates to determine its utility in this context.

Detecting Hypoxia Using The Biochemical Marker Lactate
Perhaps the most commonly used biochemical marker of hypoxia is lactate.
During anaerobic metabolism, glycolysis is sustained by the NADH-dependent reduction
of pyruvate to lactate, yielding a net of two molecules of ATP per glucose molecule
(Figure 2). When the body is reoxygenated, lactate is converted back into pyruvate and
eventually glucose in the liver at the expense of ATP (Figure 2). The diagnostic value of
lactate as a marker of hypoxia is controversial. Studies suggested that lactate is a
promising indicator of the severity of hypoxia in high-risk neonates [131] and the
neurological outcome and mortality in severely hypoxic neonates [132, 133]. Further
investigation into lactate as a marker of hypoxia revealed some inherent flaws. Lactate
levels in neonates may be increased by maternal glucose, Plasmalyte A, Ringer's lactate
infusion or bronchodilators [134-136]. Growth-retarded infants have elevated lactate
levels [137]. Maternal ephedrine administration can increase placental lactate production
and alter the fetal plasma lactate level [138]. Owing to such confounding factors lactate
may not be the most reliable marker for hypoxia. Nevertheless, clinical lactate
determinations are well established, while quantitation of purines is still generally limited
to experimental settings. Thus, lactic acid continues to be commonly used, in spite of the
ongoing debate.
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Lactate In Animal Models
Owing to evidence of acidosis in cord blood of hypoxic neonates, lactate has been
evaluated as a marker of hypoxia and asphyxia in pigs, rats, and fetal lambs (Table 4). In
the pig model, plasma lactate levels increase linearly with tissue hypoxia, exhibiting high
correlation with hypoxanthine during hypoxia as well as recovery [144]. In ex vivo
experiments using pig coronary arteries, interstitial arterial wall lactate concentrations
were observed to increase during hypoxia and fall during reoxygenation [139]. In
asphyxiated fetal rat pups, Seidl R et al. demonstrated that lactate levels increased in the
brain and blood compared to control animals [141]. Subcutaneous and striatal levels of
lactate significantly increased in asphyxiated fetal rat pups, with subcutaneous lactate
reaching a maximum around 20–21 min of asphyxia. Similarly, striatal lactate levels
reached a maximum around 19-20 min of asphyxia [142]. In the adult rat, arterial lactate
levels also increased in response to hypoxia [140]. Lastly, in fetal lambs, cerebral lactate
does not increase until there is a 30% drop in arterial oxygen saturation [143].

Lactate Marker In Full-Term Neonates
Lactate was studied in full-term infants as a marker of hypoxia and asphyxia
(Table 5). A prospective study of 4045 cord samples demonstrated elevated lactate
levels in vacuum extraction deliveries and emergency cesareans compared to standard
vaginal delivery and elective cesarean [145]. A correlation exists between lactate levels
in arterial cord blood, venous cord blood and fetal scalp blood, as well as between cord
arterial lactate, pH and base excess in infants that had ominous fetal heart rate
patterns[146]. Lactate was evaluated in CSF and blood of neonates with hypoxic-
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Table 4. Values of lactate in animal models. 1H-NMR: proton nuclear magnetic resonance;
HPLC: high pressure liquid chromatography
Species

Method Of
Measurement

Source Of
Sample

Condition Of
Animal

Recorded Level

Ref.

Pig

Spectrophotometric
kinetic enzymatic
analyzer

Interstitium

Normoxic

1.07±0.21 mmol/L

[139]

2.50±0.240 mmol/L

Arterial blood

Hypoxia
30-60 min
Normoxic
Hypoxia

13.5±4.3 mmol/L

Hypoxia
reoxygenation
Normoxic

8.3±3.3 mmol/L
88.55±0.78 μM/g

Asphyxia 5min

14.77±2.95. μM/g

Asphyxia 10min

19.63±1.36 μM/g

Asphyxia 15min

28.26±1.22 μM/g

Asphyxia 20min

36.66±3.22 μM/g

Normoxic

8.72±1.97 mM/L

Asphyxia 5min

10.35±1.15 mM/L

Asphyxia 10min

12.10±1.59 mM/L

Asphyxia 15min

14.24±1.30 mM/L

Asphyxia 20min
Normoxic

13.34±1.84 mM/L
0.7 mM

Asphyxia 2-3min

1.2±0.13 mM

Asphyxia 20-21min

2.7±0.36 mM

Asphyxia 21-22min

1.5±0.17 mM

Normoxic

3.5 μmol/g

Asphyxia 5-6min

7±1.3 μmol/g

19-20min

16.7±1.9 μmol/g

Normoxic

0.4±0.9 mmol/Kg

Hypoxic

6.7±3.6 mmol/Kg

Normoxic

88.55±0.78 μM/g

Adult
Rat

Fetal
Rat

1

H NMR

Colorimetric test

Enzymatic
spectrophotometric
end point assay

HPLC

Brain

Blood

Subcutaneous

Striatum

Fetal
Lamb

Proton magnetic
resonance
spectroscopy

Cerebral
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3.6±1.6 mmol/L

[140]

[141]

[141]

[142]

[143]

Table 5. Values of lactate in full-term neonates. HIE: Hypoxic-Ischemic Encephalopathy; 1HNMR: proton nuclear magnetic resonance; CSF: cerebrospinal fluid
Method Of
Measurement
1
H NMR

Electrochemical
test strip method

Source Of
Sample
Urine

Arterial
umbilical
blood

Roche L-640
lactate analyze
[149]

CSF

Blood

Condition Of Patient

Recorded Level

Ref.

Normoxic ≥6hr

0.09±0.02 Lactate/creatinine

[148]

Normoxic 48-72hr

0.09±0.03 Lactate/creatinine

Asphyxia (no HIE) ≥6h

0.19±0.12 Lactate/creatinine

Asphyxia (no HIE) 48-72h

0.16±0.17 Lactate/creatinine

Asphyxia (HIE) ≥6hr

16.75±27.38
Lactate/creatinine

Asphyxia (HIE) 48-72hr

0.92±1.77 Lactate/creatinine

Standard vaginal delivery

1.87±0.94 mmol/L

Vacuum delivery

2.95±1.20 mmol/L

Elective cesarean

1.44±0.10 mmol/L

Emergency cesarean

2.44±0.69 mmol/L

Normoxic

1.9±0.4 mmol/L

Asphyxiated

2.9±1.2 mmol/L

Normoxic

2.2±0.6 mmol/L

Asphyxiated

3.9±1.1 mmol/L

[145]

[147]

Table 6. Values of lactate in preterm neonates
Method Of
Measurement

Source Of Sample

Condition Of
Patient

Recorded Level

Ref.

ABL Radiometer device

Umbilical artery blood

Normoxic

29.4±2.75 mg/dl

[150]

GM 7 analyzer

Umbilical artery blood

Healthy

2750±470 μmol/L

[131]

High risk

5100±2700
μmol/L
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ischemic brain insult [147]. The role of lactate as a marker of neonatal stress was further
validated when Huang et al. reported that the urinary lactate:creatinine ratio, measured
soon after birth, may help to identify hypoxic-ischemic encephalopathy in asphyxiated
newborns [148].

Lactate Marker In Preterm Neonates
Despite the common use of lactate as an indicator of hypoxia in the clinical
setting, there are few data on the relevance of lactate in preterm neonates (Table 6). It
was shown that umbilical artery mean lactate levels are higher in preterm infants than in
term infants [150]. Chou et al. also demonstrated elevated lactate levels in preterm
infants compared to full-term ones, but this group further demonstrated elevated lactate
levels in high-risk neonates [131]. Lastly, Groenendaal et al. have proposed that lactate
may be an indicator of adverse outcome. They reported that early arterial lactate levels
were associated with a 0.47 positive and a 0.92 negative predictive value for adverse
outcomes [151]. Further research needs to be carried out in order to validate lactate as a
marker of hypoxia in preterm neonates.

Conclusions
Quantification of the presence and severity of fetal and neonatal hypoxia remains
a challenge. Identification, characterization and validation of biomarkers that swiftly
identify neonates at risk of hypoxia-induced damage are needed. It was suggested that
the therapeutic window for intervention in hypoxic-ischemic neonates is approximately 6
h following the onset of hypoxia [152]. Since the time allowed for intervention is short,
the rapid detection of direct markers of hypoxia are needed. Numerous biochemical
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markers are currently being used for the identification of hypoxia [23, 153-156]. Some of
the most promising candidates are purine metabolites, lactate, and biochemical markers
of ROS or RNS. These markers are primarily measured in body fluids, unlike ATP and
inorganic phosphate, which can be measured by tissue MRI. This review highlighted the
use of hypoxanthine, xanthine, uric acid, xanthine oxidase, MDA, nitrotyrosine and
lactate as biochemical markers of neonatal hypoxia. While the assays for some of these
markers are well established, others require further characterization [157, 158]. In
addition, several xanthine oxidase inhibitors have been evaluated as potential agents for
reduction of hypoxia-induced cellular damage [159-161]. With better diagnostic
approaches to hypoxic stress, further improvements in the understanding of affected
biochemical processes are expected and more rational interventions can be developed and
tested.

Future Perspectives
It is speculated that within the next 5-10 years, several major developments in the
field of biochemical markers of hypoxia will occur. First, new biochemical markers of
hypoxia will become established. Allantoin, a product of oxidation of uric acid, is
currently being investigated as a marker of hypoxia. Allantoin increased in premature
infants who subsequently developed chronic lung disease [162], but further research is
needed to establish it as a marker of hypoxia. Second, a combination of biochemical
markers will improve predictive value for severity of tissue damage and outcome in the
clinical setting. For this to occur, some of the current biochemical markers of hypoxia
need to be adapted to the clinical setting, and clinical studies using combinations of
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markers for higher predictive value will need to be carried out. A candidate combination
of markers could include lactate, hypoxanthine, xanthine oxidase, and MDA. This would
incorporate circulatory acid/base status, purine metabolism, ROS-generating enzyme
level and a product of lipid peroxidation into a combined evaluation of neonatal hypoxia
and tissue damage. Lastly, a greater understanding of the biochemical processes of
hypoxia will enhance the development of therapeutics. Several compounds are currently
being investigated [159, 163].
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Table 7. Executive Summary
EXECUTIVE SUMMARY
Neonatal hypoxia
 Neonatal hypoxia is a clinical condition with overt biochemical consequences.
 This condition is associated with a high morbidity and mortality rate.
 Hypoxia is associated with the production of reactive oxygen species (ROS), Reactive nitrogen species (RNS),
ATP depletion and risk of developmental abnormalities and growth retardation.
The biochemical processes of hypoxia
 The biochemical processes of hypoxia are associated with anaerobic metabolism.
 Anaerobic metabolism creates an energy-deprived state, forcing the breakdown of ATP ultimately to uric acid,
and driving the formation of lactate to sustain glycolysis.
 Purine metabolism following reperfusion requires the enzyme xanthine oxidase, which generates ROS.
 In the brain, hypoxia triggers a series of events leading to formation of ROS and RNS.
Clinical evaluation of hypoxia
Currently accepted method for diagnosis of fetal/perinatal hypoxia involves a combination of nonspecific
approaches: Apgar score, umbilical cord pH, Sarnat staging, and fetal heart rate monitoring

These methods do not correlate well with the severity of hypoxia, which may be difficult to asses do to its
numerous causes

Several fetal and maternal factors contribute to the onset and severity of hypoxia making it difficult to diagnose
with the current nonspecific clinical methods


Purine biochemical markers of hypoxia
 Promising candidate markers for quantification of the severity of hypoxia, and prediction of its sequel, are purine
degradation products
 Purine biochemical markers include hypoxanthine, xanthine, uric acid, and the enzyme xanthine oxidase
 The value of purines and xanthine oxidase as markers of hypoxia was demonstrated in animals, full-term infants
and preterm infants
ROS and RNS biochemical markers of hypoxia
Products of short-lived ROS or RNS, specifically, malondialdehyde (MDA) and nitrotyrosine, respectively, may
serve as biochemical markers of hypoxic stress

MDA measurements are a commonly used indicator of oxygen induced free radical damage.

Cerebrospinal fluid nitrotyrosine levels were used as a reliable predictor of poor neurological outcome in adults,
making it of key interest in correlating severity of hypoxia damage with outcome in neonates.


Lactate as a marker of hypoxia
 Lactate is one of the most commonly used biochemical markers of hypoxia and it is formed during anaerobic
metabolism to support glycolysis.
 The diagnostic value of lactate as a marker of hypoxia is controversial due to evidence that lactate may also be
increased by maternal glucose, Plasmalyte A, Ringer's lactate infusion or bronchodilators.
 Despite the controversy, studies have indicated that lactate is a promising predictor of the severity of hypoxia in
high-risk neonates and the neurological outcome and mortality in severely hypoxic neonates.
Conclusion
 Identification, characterization and validation of biomarkers that swiftly identify neonates at risk of hypoxiainduced damage are needed.
 Detection of the presence and evaluation of severity of fetal and neonatal hypoxia remains a challenge.
 Better diagnostic approaches to hypoxic stress will further improve the understanding of affected biochemical
processes and lead to more rational interventions.
Future prospective
 It is speculated that within the next 5-10 years, several major developments with biochemical markers of hypoxia
will occur.
 First, new biochemical markers of hypoxia will be established.
 Second, a combination of biochemical markers will improve the predictive value for severity of tissue damage and
outcome in the clinical setting.
 Lastly, improved understanding of the biochemical processes of hypoxia will enhance the development of
therapeutics.
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Abstract
Neonatal hypoxia ischemia is characterized by inadequate blood perfusion of a
tissue or a systemic lack of oxygen. This condition is thought to cause/exacerbate well
documented neonatal disorders including neurological impairment [1-3]. During
hypoxia, aerobic metabolism is switched to anaerobic pathways. Decreased adenosine
triphosphate production occurs due to a lack of oxidative phosphorylation. To
compensate for this energy deprived state molecules containing high energy phosphate
bonds are degraded [2]. This leads to increased levels of adenosine, which is
subsequently degraded to inosine, hypoxanthine, xanthine, and finally to uric acid. The
final two steps in this degradation process are performed by xanthine oxidoreductase.
This enzyme exists in the form of xanthine dehydrogenase under normoxic conditions but
is converted to xanthine oxidase (XO) under conditions of hypoxia-reperfusion [4, 5].
Unlike xanthine dehydrogenase, XO generates hydrogen peroxide as a byproduct of
purine degradation [4, 6]. Hydrogen peroxide, in combination with other reactive oxygen
species (ROS) produced during hypoxia, oxidize uric acid to form allantoin and react
with lipid membranes to generate malondialdehyde (MDA) [7-9]. Most mammals,
humans exempted, possess the enzyme uricase, which converts uric acid to allantoin. In
humans, however, allantoin can only be formed by ROS-mediated oxidation of uric acid.
Because of this, allantoin is considered to be a marker of oxidative stress in humans, but
not in the mammals that possess uricase.
We describe methods employing high-pressure liquid chromatography (HPLC)
and gas chromatography mass spectrometry (GCMS) to measure biochemical markers of
neonatal hypoxia ischemia. Human blood is used for most tests. Animal blood may also
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be used while recognizing the potential for uricase-generated allantoin. Purine
metabolites were linked to hypoxia as early as 1963 and the reliability of hypoxanthine,
xanthine, and uric acid as biochemical indicators of neonatal hypoxia was validated by
several investigators [10-13]. The HPLC method used for the quantification of purine
compounds is fast, reliable, and reproducible. The GCMS method used for the
quantification of allantoin, a relatively new marker of oxidative stress, was adapted from
Gruber et al. [7]. This method avoids certain artifacts and requires low volumes of
sample. Methods used for synthesis of MMDA were described elsewhere [14, 15].
GCMS based quantification of MDA was adapted from Paroni et al. and Cighetti et al.
[16, 17]. Xanthine oxidase activity was measured by HPLC by quantifying the
conversion of pterin to isoxanthopterin [18]. This approach proved to be sufficiently
sensitive and reproducible.

Protocol
Sample Collection And Processing
Collect blood sample in a 6ml K3E EDTA K3 tube which is kept on ice. Within 2
min of collection, centrifuge the sample at 4oC at 1500 g for 10 min. Transfer the
supernatant (plasma) to a 1.5ml microcentrifuge tube. Centrifuge at 4oC at 18000 g for
30 min. Remove the supernatant and transfer into separate microcentrifuge tubes for
purine (200μl), allantoin (50μl), MDA (100μl), and XO (120μl) analysis. Be careful not
to contaminate the samples with red blood cells. You may need to adjust the volumes of
plasma for MDA, XO, and purines based upon the total volume of plasma available.
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Table 1: Solvent changes for HPLC measurement of purine compounds.
Time

Flow (ml/min)

%A

%B

%C

1.00

0.0

0.0

100.0

1
2

16.00

1.00

0.0

0.0

100.0

3

17.00

1.00

100.0

0.0

0.0

4

22.00

1.00

100.0

0.0

0.0

5

27.00

1.00

0.0

100.0

0.0

6

32.00

1.00

0.0

100.0

0.0

7

33.00

1.00

100.0

0.0

0.0

8

38.00

1.00

100.0

0.0

0.0

9
11

39.00
45.00

1.00
1.00

0.0
0.0

0.0
0.0

100.0
100.0

Table 2: Typical retention times and max for purines and internal standard. *Determined on
HPLC using isocratic 50mM ammonium formate buffer (pH 5.5) with a flow rate of 1mL/min.
pH is in ( ).
Retention Time*

Observed max*

Reported
max[19]

Uric Acid

~ 3.5 min

288

283 (2)

11,500 (2)

Hypoxanthine

~7.0 min

248

248 (1)

10,800 (1)

Xanthine

~ 9.5 min

267

267 (2)

10,200 (2)

2-Aminopurine

~ 12.5 min

305

314 (2)

4000 (2)

60

Reported
max[19]

described in Table 1 should be used to obtain adequate peak separation: solvent A-water,
solvent B- methanol, solvent C- 50mM ammonium formate buffer, pH 5.5. Determine
the concentration of purines in the sample. Quantify hypoxanthine, xanthine, and uric
acid by obtaining peak areas at the retention times and wavelengths described in Table 2.
Determine the peak area of 2-AP. Determine the area ratios of hypoxanthine, xanthine,
and uric acid to 2-AP and convert the ratios to µmolar concentrations using standard
curves. Analyze all samples in triplicate, but only include values for later analyses if the
coefficient of variation is less than 10%.

GCMS Measurement Of Allantoin
Add 50μl of 10μM DL-Allantoin-5-13C;1-15N (internal standard) to the 50 μl
plasma set aside for the allantoin assay during sample collection and processing. Add
100 μl acetonitrile to this plasma solution. Vortex the mixture for 10-20 sec then
centrifuge at 4oC at 20000 g for 10 min. Transfer the supernatant to a GCMS vial and
dry under N2. After drying, Resuspend in 50 μl of derivatizing agent N-tertButyldimethylsilyl-N-methyltrifluoroacetamide (MTBSTFA) in pyridine (1:1 vol/vol),
cap the vials and incubate at 50oC for 2 h. This derivatization yields consistently
quantifiable m/z peaks of 398.0 and 400.0 for allantoin and DL-Allantoin-5-13C;1-15N
respectively [20]. Analyze samples on a GCMS equipped with an auto sampler.
Perform compound separation on an Agilent 122-5532G capillary column (25.7m
length, 0.25mm internal diameter). Use helium as the carrier gas at a flow rate of 1.5
ml/min. Inject derivatized product (1 µl) in split mode (split ratio 20:1, split flow 29.4
ml/min, total flow 33.8 ml/min). Set the initial column temperature at 100oC and hold at
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that temperature for 2 min before increasing it to 180oC at a rate of 10oC/min. Hold the
temperature for 4 min and then increase it to 260oC at a rate of 20oC/min. Maintain this
temperature until the end of the run. After each sample, clean the column with 1
injection of acetonitrile and 2 injections of MTBSTFA in pyridine (1:1 vol/vol).
Quantify allantoin using select ion monitoring mode while monitoring the 398.00 m/z ion
for allantoin and the 400.00m/z for the DL-allantoin-5-13C;1-15N. Convert the ion
abundance ratios of allantoin/(heavy allantoin) to micromolar concentrations of allantoin
using a prepared standard curve. All samples are analyzed in triplicate but only values
with a coefficient of variation of less than 10% are used in further analyses.

Preparing Internal Standard, Methyl Malondialdehyde (MMDA), For
MDA Analysis
Add 523μl of 3-ethoxymethacrolein and 1477μl of 7M NaOH to a 100ml round
bottom flask. Add a stirbar. Place the flask in a water bath at 45oC and stir until the
reaction has gone to completion. This should take roughly 140 min. Monitor the
progress of the reaction by removing 10μl of liquid from the flask periodically, around 10
min intervals. Dilute each sample collected to a factor of 105 using 50 mM potassium
phosphate buffer (pH 7) and measure the absorbance on the UV-Vis. Once the
absorbance at 275nm reaches roughly 0.658 the reaction is complete. As the reaction
progresses, the solution will turn yellow then orange. Allow the reaction to progress for
an additional 15 min. Add 5ml of distilled deionized water to the round bottom flask and
transfer the solution to a separatory funnel. Use an additional 5 ml of water to wash the
contents of the flask into the funnel. Extract the solution 3 times with 5 ml
dichloromethane. After each extraction discard the organic layer. After the third
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extraction, transfer the aqueous layer to a round bottom flask and rotovap to dryness.
Resuspend the product in 3ml ethanol and transfer to a pre-weighed 15ml conical tube.
Rinse the flask with an additional 2ml of ethanol and add the rinse to the conical tube.
Add 5ml benzene and incubate the tube in warm water until the product dissolves then
immediately place the tube on ice for 10 min. Centrifuge for 5 min at 15000 g and
remove the supernatant. Add 5ml ethanol and 5 ml isopropyl ether to the precipitant.
Dissolve the precipitant by incubating the tube in warm water and periodically tilting the
tube very gently. Once precipitate is dissolved, place the tube on ice for 10 min. Perform
this recrystallization 2 more times with ethanol and isopropyl ether. Some insoluble
white chunks of product may be formed. After the last recrystallization step remove as
much supernatant as possible and dry the resultant product in a Speedvac. Weigh the
conical tube with the synthesized product. Add 5ml water to the tube, vortex, and filter
out any remaining solids. Use the UV-vis spectrophotometer to determine the final
concentration of MMDA. The λmax for MMDA in 50 mM potassium phosphate buffer
(pH 7) is 274 nm with the extinction coefficient of 29900 M-1cm-1 [14].

GCMS Measurement Of MDA
Prepare a solution of 0.5mM butylated hydroxyl toluene (BHT) in ethanol by
adding 0.11 g BHT to 9ml ethanol and adjusting the final volume to 10ml. Then perform
a dilution by adding 10μl of this concentrated solution to 990μl ethanol. Prepare a
solution of 50mM phenyl hydrazine by adding 4.92μl of phenyl hydrazine to 995μl of
water in a dark microcentrifuge tube. Vortex the solution. Add 5μl 10μM MMDA to the
100μl plasma set aside for the MDA assay during sample collection and processing.
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Then add 10μl 0.5mM BHT to the MMDA/plasma mixture fallowed by the addition of
200μl 1M sodium citrate (pH 4). This pH is crucial for correct derivatization of the
sample. A higher or lower pH will result in skewed MDA levels. Dilute the final
mixture by adding distilled deionized water to a final volume of 480μl. Derivatize the
solution by adding 20μl 50mM phenyl hydrazine, capping the vials, and incubating the
solution at 25oC for 30 min on an orbital shaker. Add 1ml of hexane, vortex for 1 min,
and centrifuge at 3000 rpm for 10 min. Transfer the organic layer to a GCMS vial and
concentrate the solution to 100μl by N2 stream.
Analyze samples on a GCMS using the auto sampler. Perform compound
separation on an Agilent 122-5532G capillary column (25.7 m length, 0.25 mm internal
diameter). Use helium as the carrier gas at a flow rate of 0.6-0.8 ml/min. Inject
derivatized product (2 µl) in split mode (split ratio 20:1, split flow 23.0 ml/min, total flow
27.1 ml/min). Set the initial column temperature at 110oC and hold at that temperature
for 1 min before increasing it to 250oC at a rate of 40oC/min. Maintain this temperature
until the end of the run. After each sample, clean the column with 2 injections of hexane.
Quantify MDA using select ion monitoring mode using the 144.00 m/z for MDA and the
158.00 m/z for MMDA. Convert the MDA/MMDA ion abundance ratios to micromolar
concentrations using a standard curve. Analyze samples in triplicate and only use values
with a coefficient of variation of less than 10%.

HPLC Measurement Of Xanthine Oxidase
The detection of xanthine oxidase function is dependent on the ability to
sensitively measure the levels of a suitable substrate (pterin) as well as its product
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(isoxanthopterin). Plasma is incubated with the substrate either for 0 min (control) or 4 h,
and the incubation-dependent substrate conversion is determined. Add 240μl 0.2 M TrisHCl buffer (pH 9.0) and 4.63μl 7.083x10-3 M pterin to each tube (0 and 4h) and
preincubate them at 37oC for 5 min. Initiate the enzyme reaction by adding 60μl of
plasma to each tube. Immediately add 300μl 4% HClO4 to the 0 incubation tube but
allow the other mixture to incubate for 4 hours before quenching the reaction with 300μl
4% HClO4. After the addition of HClO4, vigorously shake the tube and then centrifuge at
4oC at 15000 g for 15 min. Remove 500μl of supernatant and neutralize by adding 20μl
of 5M K2CO3. Vigorously shake the tube and then centrifuge at 4oC at 15000 g for 15
min. Add 350μl of the neutralized solution to a microcentrifuge tube containing 1x10-8
mol 2-AP.
Analyze samples on an HPLC equipped with a scanning fluorescence detector.
Three 50 µl injections are used for each sample. Samples will be injected onto a Wacosil
5C-18-200 250 mm x 6.0 mm, 5 µm column equipped with a Supelguard LC-18-S
column guard. The following isocratic conditions should be used to obtain adequate peak
separation and identification: 95% 20mM KH2PO4 buffer (pH 2.2) and 5% methanol at a
flow rate 1ml/min. Set the excitation wavelength for the fluorescence detector at 345 nm
and the emission wavelength at 410 nm. Determine the ratios of pterine and
isoxanthopterine to 2-AP by obtaining peak areas from the fluorescence detector
spectrum. The first peak in the spectrum, ~ 5 minutes, corresponds to 2-AP. The second
and largest peak will be pterine. Isoxanthopterine peak elutes last. Obtain the difference
in the isoxanthopterine/2-AP peak area ratios between the 0 and the 4 h incubation time
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points. Use this value to calculate the XO activity from standard curves. Analyze
samples in triplicates but use only values with a coefficient of variation of less than 10%.

Representative Results
An example of the HPLC quantification of purine compounds is shown in Figure 1A.
The specific retention times and emission wavelengths of hypoxanthine, xanthine, and
uric acid permit the simultaneous quantification of purine compounds (Table 2). When
the assay is run correctly, the compounds will have adequate separation and the peak
shape will be sharp and unimodal. These peaks are then converted into concentrations,
ranges shown in table 3, through the use of a standard curve. Because sample processing
for this assay is minimal, the only sample based problems which may arise would be the
lysing of the red blood cells. If the red blood cells lyse before the samples are
centrifuged, the plasma will take on an orange/red color and cannot be used for
evaluating hypoxic ischemia. The other issues which may arise when measuring purines
involves the HPLC system and the column (Figure 1B). If there are air bubbles in the
HPLC system the retention times will shift and the HPLC pressure will fluctuate
dramatically. If the guard cartridge needs to be changed, the pressure will increase and
the peaks will widen and become bi or tri-modal.
An example of the GCMS quantification of Allantoin is shown in Figure
2. Because the mass of derivatized allantoin and derivatized heavy allantoin is known,
select ion mode can be used to identify these compounds on the GCMS. If the assay is
done correctly, two peaks will be observed at the same retention time. One
corresponding to allantoin (398.00 m/z) and the other to heavy allantoin (400.00 m/z).
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These peaks are then converted into concentrations, ranges shown in table 3, through the
use of a standard curve. If the assay is run incorrectly, and samples were not derivatized
properly, the peaks may not be present or may not be quantitatively representative. Once
again, if the red blood cells lysed the plasma cannot be used to evaluate oxidative stress
in neonatal hypoxic ischemia. The results for the quantification of MDA are similar to
those for allantoin with the exception that the two peaks are observed at different
retention times. At ~ 3 minutes retention time, a 144.00 m/z peak for MDA and at ~3.5
minutes retention time, a 158.00 m/z peak for MMDA is observed (Figure 3). These
peaks are then converted into concentrations, ranges shown in table 3, through the use of
a standard curve. If the assay is run incorrectly, or samples are not derivatized properly,
no peaks may be observed when selecting for 144.00m/z and 158.00m/z. It should be
noted that if there is an excess of lipid in the plasma from bolus oral feedings or
intravenous lipid administration, the plasma will take on a milky appearance and cannot
be used to evaluate oxidative stress in neonatal hypoxic ischemia.
An example of the HPLC-based quantification of xanthine oxidase function is
shown in Figure 4. If the assay is run correctly, three peaks should be observed with the
fluorescent detector, one for pterin, one for isoxanthopterine, and one for 2-AP. These
peaks are then converted into concentrations, ranges shown in table 3, through the use of
a standard curve. There should also be a peak corresponding to isoxanthopterin and 2-AP
on the spectrum generated from the PDA detector. If the enzyme activity is absent, the
peak corresponding to isoxanthopterin will not be seen. Because this assay measures
enzyme function, repeated freezing and thawing of the sample may alter this
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Figure 1: HPLC Chromatogram for the Identification of Purine Compounds. A).
Representative results if the assay was run correctly. B). Representative results if there is a
problem with the HPLC, column, or guard cartridge.
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Table 3: Representative ranges for purines, xanthine oxidase, malondialdehyde, and
allantoin. Max-Min (n).
Hypoxanthine

Xanthine

Uric Acid

Xanthine
Oxidase

MDA

Allantoin

-6

Term
Normoxic

1.13-19.3
(n=64)

0.02-3.69
(n=61)

107.20-726.12
(n=63)

2.47x10 3.92x10-3
(n=20)

0.44-3.76
(n=53)

NA

Term
Respiratory
Distress

1.78-12.59
(n=27)

0.07-11.8
(n=24)

225.40-653.32
(n=27)

0 - 1.03x10-5
(n=8)

0.82-2.73
(n=24)

NA

Term
Hypoxic

0.38-31.80
(n=13)

0.11-2.88
(n=13)

235.651348.13
(n=13)

1.20x10-5 236.44 (n=9)

0.95-2.15
(n=7)

NA

Preterm
Normoxic

1.54-4.39
(n=9)

0.03-1.77
(n=9)

178.92-593.49
(n=9)

2.46x10-5 5.44x10-4 (n=2)

0.95-2.74
(n=8)

2.30-5.26
(n=67)

Preterm
Respiratory
Distress

3.04-8.04
(n=2)

NA

327.56-365.11
(n=2)

NA

2.40-3.46
(n=3)

NA
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17.16 Heavy Allantoin

Allantoin

Figure 2: GCMS Spectrum for the Quantification of Allantoin.
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Figure 3: GCMS Spectrum for the Quantification of MDA.
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A

B

Figure 4: HPLC spectrum for the measurement of XO activity. A). Representative results
for the 0 min incubation time and B) Representative results for the 4 hour incubation time. Note
the higher isoxanthopterine peak for the 4 hour incubation time.
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Discussion
The methods described here permit for the evaluation of neonatal hypoxic
ischemia. This protocol combines the measurements of markers of energy deprivation,
oxidative stress, oxidative damage, and enzyme activity to gain an overall biochemical
picture of the presence or even the degree of hypoxic ischemia. Despite the usefulness of
this method, there are potential limitation. First, it takes roughly 1-2 ml of blood to
collect enough plasma to run all of the assays. This will not be a problem in adults or
children, but it poses issues when it comes to term and especially preterm neonates. We
work around this issue by prioritizing assays and diluting some of the samples if
necessary. Secondly, it can be difficult to synthesize MMDA; however, deuterated MDA
can be used as a substitute for MMDA as an internal standard.
Despite these minor limitation, the method described here provide a useful tool in
evaluating neonatal hypoxic ischemia as well as other diseases associated with alterations
in redox homeostasis. Moreover, all of these markers, with the exception of XO, can be
measured in urine, providing a non-invasive means of monitoring neonates.
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Abstract
Infants exposed to common neonatal intensive care unit (NICU) procedures show
alterations in heart rate, blood pressure and oxygen saturation; however, it is unclear if
these physiologic changes increase adenosine triphosphate (ATP) utilization, thus
potentially increasing the risk for tissue hypoxia in medically fragile neonates. Plasma
uric acid is a commonly used marker of increased ATP utilization because uric acid
levels increase when ATP consumption is enhanced. To examine the effect of a common
NICU procedure on plasma uric acid concentration, we developed a model that allows for
acute monitoring of this biochemical marker in plasma in 7- to 9-day-old rabbits. In this
pilot study, we exposed neonatal rabbits to a single heel lance 2.5 hr after catheter
placement. We measured uric acid concentration before and 30 min after the heel lance
and compared findings to levels in control animals not exposed to the heel lance. Our
pilot data shows a significant difference in uric acid concentration over time between the
control and heel lance groups (46.27.1 M vs. 54.75.8 M, respectively, P = 0.027).
Calculation of percent change from baseline showed uric acid concentration increasing in
rabbits exposed to heel lance and decreasing in control rabbits (1.5%4.7% vs. 16.14.2%, respectively, P= 0.03). These data suggest that this animal model can be
successfully used to examine the biochemical effect of common NICU procedures, such
as heel lance, on markers of ATP breakdown and purine metabolism.
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Introduction
Infants in the neonatal intensive care unit (NICU) routinely undergo painful and
invasive procedures. NICU patients are exposed to an average of 12 ± 8 painful
procedures per day and 141 ± 107 total procedures over a 14-day period [1]. Invasive
and painful NICU procedures are known to alter physiological homeostasis by increasing
heart rate and metabolism and decreasing oxygen saturation and transcutaneous PaO2
(partial pressure of oxygen in arterial blood) [2, 3]. However, it is unclear if painful
procedures increase adenosine triphosphate (ATP) utilization in excess of ATP synthesis,
increasing the risk for tissue hypoxia. Pilot data from our laboratory demonstrated
significant alterations in purine metabolism in the plasma of premature neonates
experiencing tape removal, while a recent paper by Bellieni and colleagues showed an
increase in markers of oxidative stress in the plasma of premature neonates experiencing
heel lance [4, 5]. These data suggest that common NICU procedures can lead to
enhanced ATP breakdown and oxidative stress in immature neonates.
To further examine the biochemical effects of commonly performed NICU
procedures, our laboratory developed a neonatal rabbit model for acute monitoring of
ATP breakdown and purine metabolism. The neonatal rabbit kit is an ideal NICU model
for several reasons. First, the neonatal rabbit kit has brain development similar to the
premature human neonate, with a high cortical white:gray matter ratio and undeveloped
cerebral white matter with undefined masses of neuroblasts [6] These similarities enable
evaluation of the white matter injury commonly seen in hypoxic premature neonates.
Second, unlike rats or mice, neonatal rabbits are unique in that maternal behavior is
restricted and minimal, making it possible to perform procedures and obtain results that
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are independent of stresses related to maternal separation, feeding behavior or
interference [7]. Lastly, the larger size and higher plasma volume of the postnatal rabbit
kit at age 7–9 days when compared to the postnatal rat or mouse of the same age,
approximately 15 times bigger than the neonatal rat pup, makes it possible to monitor
heart rate, oxygen saturation and blood pressure during procedures as well as collect
multiple blood samples from each animal without causing hypovolemia and significantly
altering cardiovascular homeostasis.
Based on the above-described characteristics, we examined the possible use of
neonatal rabbits as an experimental model to measure the effect of commonly performed
NICU procedures on ATP breakdown. It is well documented that when animals and
humans are challenged with increased metabolic needs, they will catabolize high-energy
phosphate bonds such as ATP [8-13]. The degradation of ATP results in increased levels
of free adenosine, which is consequently degraded to inosine and then to hypoxanthine
and xanthine and finally to uric acid (Figure 1). In humans, an increased level of uric
acid is a commonly accepted biochemical marker of hypoxia-ischemia and increased
ATP breakdown [8, 11, 13]. If common NICU procedures enhance ATP and purine
consumption, we would expect to see a significant increase in the concentration of
markers of ATP utilization, specifically uric acid, in rabbit kits exposed to procedures
commonly performed in the NICU.
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Figure 1. Exposure to neonatal intensive care unit (NICU) procedures/pain leads to adenosine
triphosphate (ATP) breakdown and uric acid metabolism. O2 = oxygen.
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Methods
Animals
We performed all experiments in accordance with approved institutional animal
care guidelines. We purchased midgestation New Zealand rabbit dams from a local
vendor and allowed them to deliver naturally at term. At postnatal day of life 5, we
transported the rabbit dam and kits to the animal care facility, where they were
maintained under approved laboratory conditions. Animals were housed in a steel cage
with a thermoregulated litter box containing nesting materials for the kits. Food and
water were made available ad libitum.

Central Catheter Placement
We performed catheter placement on a warming pad and facilitated dissection
using an OPMI-6 surgical microscope (Karl Zeiss Co., Germany) at approximately 10X
magnification. We fashioned the catheters by inserting and gluing PE-10 tubing
(Braintree, MA) into PE-50 tubing (Braintree, MA) prior to sterilization. At postnatal
day of life 7–9, neonatal rabbit kits were quickly anesthetized with 3%–3.5% isoflurane
and then maintained by mask ventilation with 1.5%–2.5% isoflurane to maximize
anesthesia while minimizing cardiorespiratory depression. Once the kits were
anesthetized, we made an incision in the neck to the right of the ventral midline and
isolated the internal jugular vein from surrounding tissue. We made a second skin
incision inferior to the left scapula and tunneled a venous catheter subcutaneously from
the back incision to the neck incision. We then inserted a 25-gauge butterfly into the free
end of the PE-50 tubing and filled the catheter with heparinized saline (20 units/ml). We
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ligated the distal internal jugular vein with 8-0 ophthalmic nylon and made a venotomy
with a 25-gauge needle. We then passed the catheter antegrade through the venotomy at
a predetermined distance to reside at the junction of superior vena cava and right atrium.
We secured the catheter to the proximal vein using 6-0 silk after ensuring patency, filled
it with heparinized saline, and locked it with gentamicin (120 microgram/ml). We closed
subcutaneous tissues in a routine manner with 6-0 vicryl and maintained catheter patency
by flushing with heparinized saline (10 units/ml) after each blood draw, as described
below. We employed standard aseptic techniques and monitored the rabbit kits
continuously for heart rate, respiratory rate and temperature. After completing the
catheterization procedures, we discontinued anesthesia. All rabbit kits recovered
immediately and were observed to be active and moving freely within 15–30 min. They
remained awake (unanesthetized) and active for the duration of the study.

Blood Sampling Procedure For Acute Monitoring Of Plasma Uric Acid Concentration
To examine the effectiveness of this animal model in acutely measuring the
effects of common NICU procedures on plasma uric acid concentration, we randomized
rabbit kits to either a time-control or a heel lance group. We used data gathered from the
time-control group to determine the optimal timing of the heel lance procedure in the
experimental animals as described below. For all animals, we drew blood from the
jugular catheter at specific time points: immediately after catheter insertion (0 hr) and at 2
hr, 2.5 hr and 3 hr after insertion (Figure 2). Study conditions (lighting, noise,
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Figure 2. Time line of experimental procedures.
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temperature) were similar during both time-control and heel lance procedures. Animals
in the time-control group were allowed to move around the cage freely for the entire
study after catheter placement; animals in the heel lance group were allowed to move
freely until 2.5 hr after surgery when they were exposed to the heel lance procedure.

Heel Lance Procedure.
Based on data gathered in the time-control animals (see “Results,” Figure 3), we
exposed rabbit kits in the heel lance group to heel lance (Accuchek, Roche Diagnostics
Basel, Switzerland) at 2.5 hr after anesthesia and catheterization. We used a lance depth
of 2.3 mm for each heel lance procedure due to the presence of fur on the rabbit’s heel
and to ensure that the procedure would lead to a visible single drop of blood.

Blood Processing And Uric Acid Analysis
Each blood sample was collected into an EDTA tube in the surgical sweet and
transported it to a lab in the department, on ice, where lab personnel placed the samples
into a Fisher Scientific AccuSpin 1R Centrifuge (Fair Lawn, NJ). Samples were
centrifuged for 20 min at 1,500 g and 4oC. The plasma was removed, transferred to
separate Eppendorf tubes and centrifuged in a Beckman Microfuge 22R centrifuge
(Fullerton, CA) for 30 min at 18000 g, 4oC. Each supernatant, 250µl, was then
deproteinated using a Microcon centrifugal filter device (Millipore Corp., Bedford, MA)
with a 10K molecular weight cutoff by spinning the loaded device for 90 min at 14000 g
and 4oC. Filtrate was removed and 200 µl were transferred to an Eppendorf tube
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containing 1X10-7 mol of 2-aminopurine as internal standard. Samples were stored at 80oC until analysis.
For measurement of uric acid, each blood sample was analyzed using high
pressure chromatography (HPLC; Waters 600E, Waters 996 PDA, Millipore Corp.) by
injecting 50 µl of sample onto a Supelcosil LC-18-S 15cm X 4.6 mm, 5 µm column
(SGE: Austin, TX) with the following isocratic conditions: 50mM ammonium formate
buffer, pH 5.5, flow rate 1.0 ml/min. Uric acid and the internal standard, 2-aminopurine,
were quantitated by obtaining peak areas at the appropriate retention times (~3.0 and
~12.0 min, respectively) and absorbance wavelengths (288 and 305, respectively). The
area ratio of uric acid to 2-aminopurine was determined and converted into concentration
using standard curves. Samples were analyzed in triplicate and values with a coefficient
of variation less than 10% were included in the final analysis.

Statistical Analyses
We assessed assumptions of normality and equal variance. We used independent
samples t-test to analyze continuous data and reported them as the mean and standard
. We assessed repeated measures ANOVA for one betweensubject factor (group) and one within-subject factor (time) to evaluate the effect of the
two procedures (control vs. heel lance) on plasma uric acid concentration over time using
interaction terms in the general linear model. We calculated percent change in uric acid
between 0-min (baseline) and 30-min (postprocedure) values as follows (Eq. 1):

([30 min] – [0 min])/[0min]) x 100
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Eq. 1

We performed all statistical analyses using SPSS Statistics for Windows Version 19 and
considered differences to be significant at p < .05.

Results
Central Catheter Placement
Using the jugular vein, we were successful in obtaining multiple blood samples
from a total of 11 out of 15 rabbit kits (73% success rate), 5 of which were in the control
group and 6 of which were in the heel lance group. We were not able to obtain multiple
blood samples in the other 4 rabbits due to catheter dislodgement or failure of the line to
draw, possibly due to kinking or clotting.

Stabilization Of Plasma Uric Acid Concentration Post Central Catheter
Placement
We measured uric acid concentrations in plasma over multiple time points to
determine when this marker stabilized after jugular catheterization. We found in 5
control rabbit kits that uric acid values began to fall at the 2.5- and 3-hr time points,
suggesting achievement of steady-state ATP metabolism (Figure 3). Thus we
determined that the 2.5-hour time point could be used to explore the effect of procedures
on biochemical markers of ATP breakdown.

Effect Of Heel Lance On Uric Acid Levels
We found significant differences in uric acid concentration over a 30 min time
period between the control group and the heel lance group (46.2  7.1 M vs. 54.7  5.8
M, respectively, p = .027; Figure 4). Whereas uric acid concentration decreased over
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Figure 3. Uric acid concentration time course in control rabbit kits (n = 5; mean±SD).
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time in control rabbits, it increased over time in rabbits exposed to heel lance (repeated
measures, p < .05; Figure 4). Calculation of percent change from baseline confirmed
that uric acid concentration was increasing in the heel lance group while decreasing in the
control group (1.5%  4.7% vs. -16.1  4.2%, respectively, p = .03).

Discussion
Our preliminary work showed that neonatal rabbits can successfully be used as a
model for acutely monitoring the effects of common NICU procedures on ATP
metabolism and breakdown. After collecting blood at four different time points post
catheter placement, we observed that plasma uric acid levels began decreasing at the 2.5and 3-hr time points. This decrease was most likely due to the enzymatic conversion of
uric acid to allantoin or to urinary excretion, which is to be expected in control rabbits.
In the absence of enhanced ATP breakdown, plasma uric acid levels will gradually
stabilize or decrease [14]. The conversion of uric acid to allantoin occurs through the
action of uricase, an enzyme present in rabbits [15, 16].
At the 2.5- and 3-hr mark, we noted an opposite trend in rabbits exposed to a
single heel lance (Figure 4). This increase in plasma uric acid concentration suggests
that this common procedure can increase ATP utilization and breakdown. It is unclear if
this increase in energy needs will exacerbate hypoxia in sick premature neonates. Further
studies are needed to determine if enhanced ATP utilization due to exposure to common
NICU procedures induces a hypoxic response, which may lead to inflammation and
organ damage [17, 18].
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Figure 4. Differences in uric acid concentration over time in rabbits without heel lance (control
group, n = 5) and rabbits subjected to heel lance (heel lance group, n = 6). *Repeated measures
ANOVA.
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One comment regarding difficulties we encountered in the use of this animal
model might be helpful for future investigators. After evaluating several potential sites
for central catheter placement, we found the highest success with the internal jugular
vein. Although attempts to insert catheters into the femoral vein were moderately
successful, the catheters fell or kinked when the rabbits recovered from surgery and were
permitted to move around freely. We disregarded other potential catheter insertion sites,
such as the ear vein or the cephalic vein, because of vessel size and high incidence of
vessel collapse when a sample is being aspirated. Even with the choice of the internal
jugular vein, only 11 of the 15 catheters placed remained patent and allowed for repeated
blood draws.
Our pilot study shows preliminary data documenting the use of this animal model
to examine the relationship between a single commonly performed NICU procedure, heel
lance, and markers of ATP breakdown. The model could also be used to study the
biochemical effects of a combination of NICU procedures performed sequentially,
leading to an examination of the biochemical effects of repetitive pain- or non-paininducing procedures. The rabbit’s larger size relative to rats and mice would allow the
measurement of other relevant biochemical markers of hypoxia, ATP breakdown or
oxidative stress, including plasma concentrations of ATP, adenosine diphosphate (ADP),
adenosine monophosphate (AMP), adenosine, malondialdehyde or F2 isoprostane.
Although not performed in this current study, future investigators could develop and
validate measures of pain specific to neonatal rabbits for use in rabbits exposed to painful
procedures, which would allow for the examination of the relationships among
biochemical markers of ATP utilization, hypoxia and behavioral markers of pain.
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Because the animals survive the catheterization and blood sampling procedure, the model
could also be used to investigate the possible link between procedural pain, increased
ATP utilization and organ impairment, such as white matter injury, through magnetic
resonance imaging and spectroscopy.

Relevance To Nursing Practice And Research
NICU nurses perform many painful and nonpainful procedures on the neonates in
their care. Although the effects of these procedures on heart rate and oxygen saturation is
clearly visible at the bedside, it is unclear whether these alterations increase ATP
utilization and decrease ATP synthesis, potentially increasing the risk of tissue hypoxia in
fragile neonates. Researchers have hypothesized that hypoxia from pain and stress
during many weeks and months in the NICU may be one contributing factor to white
matter injury. However, this link remains speculative because the mechanisms that link
pain with organ damage remain elusive. Use of this model may help elucidate the
relationship between single, multiple or repetitive NICU procedures and ATP breakdown
and hypoxia. Because the animals are allowed to survive after sample collection, the
effect of NICU procedures on organ damage could be elucidated through multiple
imaging modalities (magnetic resonance imaging and spectroscopy) or tissue assays.
Data from these studies could be used to test efficacy of treatment strategies and to
develop innovative nursing interventions to prevent and treat potentially adverse
consequences of commonly performed NICU procedures in premature neonates [19, 20].
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Abstract
Preterm neonates exposed to painful NICU procedures exhibit increased pain
scores and alterations in oxygenation and heart rate. It is unclear whether these
physiologic responses increase the risk of oxidative stress. Using a prospective study
design, we examined the relationship between a tissue-damaging procedure (TDP, tape
removal during discontinuation of an indwelling central arterial or venous catheter) and
oxidative stress in 80 preterm neonates. Oxidative stress was quantified by measuring
uric acid and malondialdehyde (MDA) concentration in plasma obtained before and after
neonates experienced a TDP (n=38) compared to those not experiencing any TDP
(control group, n=42). Pain was measured before and during the TDP using the
Premature Infant Pain Profile (PIPP). We found that pain scores were higher in the TDP
group compared to the control group (median scores: 11 and 5, respectively, P<0.001).
Uric acid significantly decreased over time in control neonates but remained stable in
TDP neonates (132.76M to 123.23M vs.140.50M to 138.9M, P=0.002). MDA
levels decreased over time in the control group but increased in the TDP group (2.07M
to 1.81M vs. 2.07M to 2.21M, P=0.01). We found a significant positive correlation
between PIPP scores and MDA. Our data suggest a significant relationship between
procedural pain and oxidative stress in premature neonates.
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Perspective
This article presents data describing a significant relationship between
physiological markers of neonatal pain and oxidative stress. The method described in
this paper can potentially be used to assess the direct cellular effects of procedural pain as
well the effectiveness of interventions performed to decrease pain.

Introduction
During a typical stay in the neonatal intensive care unit (NICU), a newborn often
experiences numerous painful procedures in the course of monitoring and treatment.
Contrary to previously held convictions, premature neonates are able to perceive pain as
demonstrated by several pain scoring methods [1, 2]. Such methods, however, tend to
rely on a neonate’s alertness and ability to react expressively to the painful experiences.
Consequently, caregivers are reluctant to treat pain if there appears to be no clear
demonstration that it is occurring or if no immediate untoward effects are observed [3].
An approach that allows the measurement of a systemic reaction to a painful stimulus has
the potential benefit of providing objective means of evaluating the pain as well as the
effectiveness of its treatment.
It is well documented that exposure to painful procedures often results in
tachycardia, which increases energy expenditure and oxygen consumption [4]. However,
there are currently few data that quantify the effect of increase oxygen consumption on
ATP metabolism. Theoretically, an increase in oxygen consumption should increase the
utilization and degradation of ATP to its purine byproducts, specifically uric acid (Figure
1). We made this observation in a pilot study from our laboratory in which we reported
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Figure 1: Pathway from ATP to uric acid and lipid to MDA
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increased uric acid concentration in rabbit kits subjected to a single heel lance [5].
Because the process of purine degradation can result in the production of hydrogen
peroxide, markers of oxidative stress can theoretically increase. This was observed by
Belliene et al. who showed increased markers of oxidative stress in the plasma of
premature neonates experiencing a single heel lance [6]. However, no studies to date
have examined the relationship between behavioral and physiological markers of pain
and plasma markers of ATP utilization and oxidative stress. Specifically, do markers of
ATP utilization and oxidative stress increase as pain scores increase?
To explore this question, we studied two groups of preterm neonates: one group
experiencing a common tissue damaging procedure (TDP group) and a second group not
experiencing any TPD (control group). The TDP was tape removal associated with the
discontinuation of a central arterial or venous catheter. Pain was measured before and
during the TDP using the Premature Infant Pain Profile (PIPP), whose components
include physiological (gestational age, heart rate, oxygen saturation) and behavioral
(alertness and facial expressions) markers. ATP degradation was quantified by
measuring uric acid levels and oxidative stress was quantified by measuring
malondialdehyde (MDA) in plasma obtained before and after the TDP. Uric acid is a
well-known end product of purine metabolism whose concentration is associated with
increased ATP utilization, hypoxia, ischemia or increased ROS (Figure 1) [7].
Malondialdehyde is a thiobarbituric acid–reacting substance that is formed by the action
of ROS on lipid membranes (Figure 1) [8, 9]. Its use as a marker is relevant because the
study of oxidative stress and pain in neonates is relatively recent and the association of
pain with elevated MDA was reported in adults. Elevated MDA concentrations were
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observed in adult patients with vascular related pain [10], young women with
dysmenorrheal pain [11, 12], adults with neuropathic pain [13] and adult patients with
acute abdominal pain [14]. More recently, MDA and 8-hydroxyguanosine were reported
to significantly correlate with pain intensity in patients with temporomandibular joint
disease [15].
Evaluation of the effects of pain in premature neonates is challenging. We are
presenting biochemical evidence that a single painful procedure is associated with a
system wide perturbation in purine metabolism. Furthermore, we show that a single TDP
is also associated with elevated MDA levels (correlated with the PIPP score) suggesting
distant effects in the form of oxidative damage to lipid membranes.

Methods
Subject Enrolment And Sampling Procedure
We conducted a prospective cohort study at the Loma Linda University
Children’s Hospital NICU. The Loma Linda University Institutional Review Board
approved study protocol and informed consent documents. Families were approached for
consent as soon as possible after birth.
Preterm infants less than 37 weeks gestation that met the following inclusion
criteria were considered for enrollment: 1) weight of more than 1000 grams at time of
enrollment, 2) arterial or central venous catheter in place, 3) no signs or symptoms of
hypoglycemia, hypovolemia, hypoperfusion, hyperbilirubinemia, clinical sepsis, pallor or
moderate to severe respiratory distress, 4) absence of intraventricular hemorrhage grade 3
or higher and 5) parental consent. Exclusion criteria included 1) multiple congenital
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abnormalities 2) facial malformation, 3) complex congenital heart disease 4) receiving
analgesia or sedation and 5) endotracheal intubation.
After parental consent was obtained, investigators collaborated with the clinical
staff to obtain from a central catheter, approximately 0.8 ml of blood, before and 30
minutes after the TDP to measure levels of uric acid and MDA. In control neonates,
similar samples were obtained at 0 and 30 minutes from baseline. The time period of 30
minutes after TDP for blood sample collection was based on previous investigations
which showed plasma levels of MDA significantly increasing 15-30 minutes after
ischemia-reperfusion [16, 17] and remaining elevated up to 2 hours later [18]. Our pilot
study in rabbit kits also showed elevations of uric acid thirty minutes after a single heel
lance [5]. To isolate the effects of TDP, subjects were given at least one hour of quiet
time in which no TDPs were performed before baseline blood samples were drawn and
no additional TDPs were performed during the study period. Samples were centrifuged
within five minutes to separate cells from plasma which was then stored at -80°C. All
stored plasma samples were analyzed within one week of acquisition.

Pain Assessment
To assess pain, we used the Premature Infant Pain Profile (PIPP), an instrument
that was designed to assess acute pain in preterm neonates [19]. The scoring system
includes seven items, each graded from 0 to 3. Two items describe baseline
characteristics of the neonate (gestational age and behavioral state), two items are derived
from physiologic measurements (heart rate and oxygen saturation), and three items
describe facial actions (brow bulge, eye squeeze, and nasolabial furrow). Gestational age,
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behavioral state, heart rate and oxygen saturation were assessed and recorded by a trained
research nurse (LS) at the bedside. Facial actions were assessed and scored by a
neonatologist who was blinded to group assignment (KH), who had undergone training in
the use of the PIPP and was experienced in observing and quantifying facial actions.
Previous work on validation of the PIPP score showed an ability to differentiate painful
from non-painful or baseline events (F = 48; P = .0001), with interrater reliability
coefficients of 0.93 to 0.96 and intrarater reliability coefficients were 0.94 to 0.98 [19-21].

Measurement Of MDA
Plasma MDA levels were determined using an adaptation of the selected ionmonitoring gas chromatography-mass spectrometry (GCMS; Agilent, Santa Clara, CA)
analysis of phenylhydrazine-derivatized plasma, as described by Cighetti et al [22].
Specifically, the sample was prepared by the mixture of 0.1 ml plasma, 0.26 nmol methyl
malondialdehyde (MMDA), 5 nmol butylated hydroxytoluene (10 µl of 0.5 mM) (Sigma,
St. Louis, MO), 0.2 ml citrate buffer (0.4 M, pH 4.0), and deionized water, up to a final
volume of 480 µl. Then 20µl 50 mM phenylhydrazine (1 µmol) (Aldrich, St. Louis, MO)
was added as the derivatizing agent. After 30 min incubation at 25C, the samples were
extracted with 1 ml hexane, vortexed for 1 min and centrifuged (3000 rpm, 10 min) at
25C. The organic phase was removed, concentrated by nitrogen stream to 100 µl, and
analyzed by GCMS, in selected ion monitoring mode (injection volume of 2 µl). Ion
144.00 was monitored for MDA, and ion 158.00 for MMDA. The ion abundance ratios
were converted to micromolar concentrations by use of a standard curve. All
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measurements were performed in triplicate. Values with coefficients of variation of less
than 10% were included in the final analyses.
The internal standard, MMDA, was synthesized using a modified method of
Paroni et al [23]. Briefly, 2-methyl-3-ethoxyprop-2-enal (Sigma; St. Louis, MO) was
suspended in 7 M NaOH and stirred for 150 min. This was diluted with 5 ml of water
and extracted with three 5 ml volumes of CH2Cl2. After that, the water was evaporated
from the aqueous layer. The residue was crystallized once from 5 ml ethanol and 5 ml
benzene and then three times from 5 ml ethanol and 5 ml diisopropyl ether. The resulting
white powder was diluted in water, filtered, and stored at -80°C.

Measurement of Uric Acid
Plasma was transferred to separate Eppendorf tubes, and immediately centrifuged
within 5 minutes in Beckman Microfuge 22R (Fullerton, CA) for 30 minutes at 18000 x
g, 4C. The supernatant was immediately transferred to Microcon centrifugal filter
devices (Millipore Corp.; Bedford, MA), 200 µl per device, and spun for 90 min at 14000
x g, 4°C. Filtrate was removed, and 150 µl was transferred to an Eppendorf tube
containing 1 x 10-7 mol of 2-aminopurine (Sigma, St. Louis, MO) as the internal standard.
Analysis was done the same day using high performance liquid chromatography (HPLC;
Waters 996 PDA, 715 Ultra Wisp Sample Processor; Millipore Corp) or the tubes were
frozen at -80°C until analysis could be performed. Previous HPLC analysis demonstrated
that uric acid values remained stable despite freezing.
Three 45 µl injections were used for each sample. Samples were injected onto a
Supelcosil LC-18-S 15 cm x 4.6 mm, 5 µm column (Supelco, Sigma Aldrich, St. Louis,
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MO), with the following isocratic conditions: 50 mM ammonium formate buffer, pH 5.5,
flow rate 1.0 ml/min. Uric acid concentration was quantitated by first obtaining
integrated peak areas for uric acid and for 2-aminopurine at appropriate retention times
and wavelengths, as described by our laboratory [24]. The peak area ratios of uric acid to
2-aminopurine were determined and converted to micromolar concentrations using
standard curves. Samples were analyzed in triplicates and values with coefficients of
variation of less than 10% were included in the final analyses. The limit of detection for
uric acid was 5.0 µM.

Statistics
At the time our study was planned, there were no studies that had examined the
relationship between pain and oxidative stress in premature neonates. We based our
sample-size calculation on our pilot study that compared MDA and uric acid
concentration in neonates born by elective cesarean section to those born by vaginal
birth[24]. Based on that calculation, 35 subjects per group were required to demonstrate
a difference between groups with 80% power and  = .05 (Sample Power 2.0, SPSS Inc,
Chicago, IL). We recruited additional subjects per group to account for data-collection
errors. The total sample size was 80 infants (Control n = 42 and TDP n = 38).
Assumptions of normality and equal variance were assessed. Demographic data
for categorical variables were analyzed using Chi-square test. Repeated measures
ANOVA for one between subject factor (group) and one within subject factor (time) were
assessed to evaluate the effect of the procedure (control vs. TDP) on plasma uric acid and
MDA concentrations over time. Interaction terms in the General Linear Model were used

103

for this purpose. Percent change in uric acid, as well as MDA, between baseline and
thirty-minute values were calculated as follows (Eq. 1):

(([30min] – [0min]) / [0min]) x 100

Eq. 1

Correlations between uric acid, MDA and biobehavioral markers (PIPP) were examined
using Spearman’s rho. All statistical analyses were performed using SPSS Statistics for
Windows Version 17. Differences were considered significant at P < 0.05.

Results
General Results
Subject recruitment occurred from July 2007 to August 2009. After obtaining parental
consent, samples were obtained from 80 subjects that met study criteria. As described in
Table 1, no significant differences in demographics were demonstrated between the
control and TDP group. The clinical characteristics and the environmental condition of
subjects at the time of sampling were also compared (Table 2). At the time of sampling,
no significant differences were observed in mode of ventilation, baseline oxygen
saturation, postnatal age, fraction of inspired oxygen (FiO2), hemoglobin, acuity (as
measured by SNAPPE-II), environmental noise, kidney function (as measured by BUN
and creatinine) and number of exposure to TDPs (Table 2).
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Table 1. Subject demographics. TDP: tissue damaging procedure; NS: not significant. Data are
Mean  SD. *Independent samples t-test, +Chi-square
No Procedures

Single TDP

Number of Subjects

42

38

Birth Weight (g)

1644 ± 486

1540 ± 389

NS

Estimated Gestational
Age (Weeks)
Gender (%)

31.2 ± 3

30.7 ± 3.3

NS

Male 54.1

Male 54.1

NS+

Apgar-1 minute

6±2

6±3

NS

Apgar-5 minute

8±2

7±3

NS

Race (%)

Caucasian 52.4
Hispanic 23.8
African American 14.3
Asian 7.1
Not Documented 2.4

Caucasian 39.5
Hispanic 44.7
African American 10.5
Asian 5.3
Not Documented 0.0

NS+
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P Value*

Table 2. Physiological and Environmental Conditions at Time of Sampling. CPAP:
continuous positive airway pressure, NIPPV: noninvasive positive pressure ventilation, NS: not
significant. Data are mean±SD, * Independent samples t-test.

FiO2
Mode of Ventilation

No Procedures

Single TDP

P Value*

0.24 ± 0.05

0.24 ± 0.07

NS

Room air = 24 (57.1%)
Nasal cannula = 9 (21.4%)
Nasal CPAP = 6 (14.3%)
NIPPV = 3 (7.1%)

Room air = 26 (68.4%)
Nasal cannula = 4 (10.5%)
Nasal CPAP = 5 (13.1%)
NIPPV = 3 (7.9%)

NS

Baseline oxygen saturation (%)

97 ± 2.8

97 ± 3.6

NS

Postnatal age (days)

20 ± 12

20 ± 15

NS

Weight (g)

1850 ± 515

1890 ± 568

NS

Hemoglobin (mg/dL)

12.7 ± 2.2

13.2 ± 2.2

NS

SNAPPE-II score

7.9 ± 3.6

7.6 ± 5.5

NS

Blood urea nitrogen (mg/dL)

16.8 ± 10.6

14.8 ± 8.3

NS

Creatinine (mg/dL)

0.47 ± 0.19

0.46 ± 0.18

NS

No. of TDPs from birth to time
of sampling

95 ± 69

107 ± 96

NS

Environmental noise (dB)

51 ± 5

53 ± 4

NS

Table 3. Pain Scores as Measured by PIPP. NS: not significant, * Mann-Whitney U test

Baseline pain score (median)
Procedural pain score (median)

No Procedure (N=42)
3 (0-7)

TDP (N=38)
3 (0-8)

P value *
NS

5 (0-11)

11 (3-19)

< 0.001
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Procedural Pain Score As Measured By PIPP
As expected, neonates in the TDP group had significantly higher procedural pain
scores compared to the control group (Table 3). Median procedural pain scores were as
follows: control group: 5 (min-max 0-11) and TDP group: 11 (min-max 3-19), P < 0.001
(Table 3).

Differences Between Baseline And Post-Procedure Uric Acid And
MDA Levels In Control Vs. TDP Groups
There were no significant differences in baseline uric acid and MDA levels
between control and TDP groups. However, although uric acid levels decreased over
time in the control group, uric acid levels remained unchanged in the TDP group (Figure
2). More importantly, we saw a significant increase in MDA over time in the TDP group
that was not observed in the control group (P = 0.02) (Figure 2).

Correlation Between PIPP Pain Score And MDA
We found significant correlations between pain scores and MDA (Pearson
correlation, 0.283, P = 0.012). As the pain score increased, MDA levels also increased.
In addition, we found significant correlations between procedural heart rate and MDA
concentration (Correlation Coefficient 0.286, P = 0.014). We observed that as heart rate
increased, MDA concentration also increased. More importantly, we also found a
significant correlation between MDA concentration and oxygen saturation; as oxygen
saturation decreased, MDA concentration increased (Correlation coefficient, 0.454, P
<0.001). We found no significant correlation between plasma uric acid levels and total
PIPP pain scores.
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Figure 2: Plasma [Uric Acid] and [MDA] at baseline and 30 minutes post-TDP.
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Discussion
Premature neonates in the intensive care unit have reduced endogenous substrate
fuel stores and metabolic reserve [25]. Their ability to respond to acute stressors is
limited due to their physiologic immaturity, which impedes their ability to mobilize
substrate during catabolic metabolism [26]. Their response to routine NICU procedures
often include significant alterations in transcutaneous oxygen levels (TcPO2) and heart
rate [27, 28]. Because neonates have fixed stroke volumes, acute changes in heart rate
can potentially reduce preload, decrease cardiac output and cause tissue hypoperfusion,
increasing the risk of ischemia before compensatory mechanisms take effect. Ischemia
combined with decreased arterial oxygen tension can contribute to increased ATP
utilization in the face of decreased ATP synthesis. This can lead to enhanced degradation
of ATP to adenosine diphosphate (ADP) and adenosine monophosphate (AMP) [29].
Further degradation leads to dramatic increases in adenosine levels. In turn, adenosine is
converted to inosine and subsequently to hypoxanthine, xanthine, and uric acid (Figure
1). During conditions of decreased ATP supply, the enzyme xanthine oxidase is
activated catalyzing the conversion of hypoxanthine to xanthine and xanthine to uric acid,
while generating reactive oxygen species [30]. In this context, there has been little
research evaluating the link between painful procedures, increased ATP utilization and
oxidative stress in premature neonates.
Our data demonstrate a significant relationship between procedural pain and
MDA, a well-accepted marker of oxidative stress. Specifically, we observed an increase
in MDA in neonates exposed to a single painful procedure compared to those exposed to
no such procedure. None of the neonates in this study had conditions that were shown to
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increase plasma MDA concentration such as moderate to severe respiratory distress,
elevated FiO2 requirements, lipid infusions, hyperbilirubinemia [31, 32] or clinical signs
of septicemia [33]. Instead, the elevated MDA is consistent with an increase in the
production of reactive oxygen species secondary to enhanced ATP degradation (Figure
1) in response to increased energy requirements and reduced oxygenation brought about
by the painful procedure. Elevations in heart rate and reductions in oxygen saturation
significantly correlated to elevated MDA levels. Further studies are required to
investigate this mechanism as well as other possible mechanisms that may increase MDA
such as pain-related tissue injury, inflammation and cytokine production. To validate the
relationship between procedural pain and oxidative stress, it will also be important to
measure other oxidative stress markers, such as damage to DNA (8-hydroxy-2'deoxyguanosine), lipids (4-hydroxy-2-noneal, isoprostanes, isofurans) and nitration of
proteins (nitroalbumin, nitrotyrosine, 3-nitro-4-hydroxyphenylacetic acid (NHPA) and
para-hydroxyphenylacetic acid) in plasma and other biological fluids [34-36].
Our findings have important implications for clinical practice. Because neonates
are exposed to multiple painful procedures per day [37, 38], previous investigations have
focused on examining and decreasing the painful effects of these procedures. A number
of interventions, such as the use of sucrose [39-41], pacifiers [41, 42], or morphine [43,
44] have been successful in decreasing signs of pain, but studies investigating the
possible biochemical sequelae of painful procedures in neonates are needed. If exposure
to multiple painful procedures is shown to contribute to oxidative stress, biochemical
markers of such stress might be useful to evaluate mechanism-based interventions that
could decrease the adverse effects of exposure to these procedures.
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Although our findings are novel in the neonatal population, our study was
performed without randomization. The painful procedure (tape removal) was a clinical
requirement necessary in the normal course of care in the NICU setting, and no additional
painful procedures were employed solely for the benefit of a randomized experimental
protocol. However, as shown in Table 1, the demographic and clinical characteristics of
subjects in both the control and TDP groups were not significantly different. All of the
subjects were clinically stable premature neonates, with minimal oxygen requirements
and similar clinical acuity status. Randomized trials that examine the biochemical effect
of painful procedures in more acutely ill neonates with higher SNAPPE II scores are
needed.

Conclusion
Our data demonstrate an important relationship between exposure to a single
painful procedure and oxidative stress. Because neonates are exposed to many painful
procedures during hospitalization, it is important to further examine the effect of single,
multiple and accumulated TDPs in a randomized clinical trial. Mechanistic studies that
will determine whether or not procedure-related increases in oxidative stress exacerbate
preexisting pathological conditions or trigger development of new abnormalities would
provide insight.
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Abstract
Objective
To examine the effects of sucrose on pain and biochemical markers of adenosine
triphosphate (ATP) degradation and oxidative stress in preterm neonates experiencing a
clinically required heel lance.
Study Design
Preterm neonates that met study criteria (n = 131) were randomized into 3 groups:
(1) control; (2) heel lance treated with placebo and non-nutritive sucking; and (3) heel
lance treated with sucrose and non-nutritive sucking. Plasma markers of ATP
degradation (hypoxanthine, xanthine, and uric acid) and oxidative stress (allantoin) were
measured before and after the heel lance. Pain was measured with the Premature Infant
Pain Profile. Data were analyzed by the use of repeated-measures ANOVA and
Spearman rho.
Results
We found significant increases in plasma hypoxanthine and uric acid over time in
neonates who received sucrose. We also found a significant negative correlation between
pain scores and plasma allantoin concentration in a subgroup of neonates who received
sucrose.
Conclusion
A single dose of oral sucrose, given before heel lance, significantly increased
ATP use and oxidative stress in premature neonates. Because neonates are given
multiple doses of sucrose per day, randomized trials are needed to examine the effects of
repeated sucrose administration on ATP degradation, oxidative stress, and cell injury.
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Background
Premature neonates experience many painful procedures as part of their standard
care in the neonatal intensive care unit [1, 2]. To prevent or treat procedural pain, the use
of oral sucrose is recommended by many national and international clinical guidelines on
the basis of results from multiple randomized clinical trials in which investigators
determined sucrose to be effective in reducing signs of pain [3]. However, there are no
studies to date in which investigators examine the effects of sucrose, a disaccharide of
fructose and glucose, on neonatal cellular adenosine triphosphate (ATP) metabolism,
despite the well-documented relationship between fructose metabolism and reductions in
ATP synthesis in adult animals [4], in children ages 11 months to 12 years [5], and in
healthy adults [5, 6].
Inhibition of ATP synthesis, as a consequence of sucrose administration, may
reduce a premature neonate's already modest ATP stores [7]. In addition, evidence shows
that the administration of sucrose does not attenuate the tachycardia that often
accompanies painful procedures [8]. In neonatal pigs and newborn lambs, tachycardia
significantly increased glucose oxidation and myocardial oxygen requirement [9], which
paralleled significant reductions in phosphocreatine/ATP and significant elevations in
adenosine diphosphate (ADP) and inorganic phosphate [10]. More importantly, sucrose
may not be an effective analgesic as evidenced by its lack of impact on neonatal
nociceptive circuits in the brain and spinal cord [11]. Together, these considerations
imply that oral sucrose administration may alter ATP metabolism and may have adverse
cellular effects in neonates with limited energy stores.
The aim of this study is to examine the effects of a single dose of oral sucrose on

119

behavioral/physiological markers of pain and biochemical markers of ATP metabolism
and oxidative stress in premature neonates experiencing a clinically required heel lance.
The heel lance was chosen because it is a frequent painful procedure in the neonatal
intensive care unit, as shown in 26 different clinical trials [12]. Pain was quantified using
the Premature Infant Pain Profile (PIPP) [13], ATP metabolism was quantified by
measuring plasma concentrations of purines (hypoxanthine, xanthine, and uric acid),
which are well-documented markers of ATP use and breakdown, and oxidative stress,
measured as plasma concentrations of allantoin, a well-accepted in vivo free radical
marker [14].

Methods
Subject Enrolment And Sampling Procedure
We conducted a prospective double-blind randomized controlled study at Loma Linda
University Children's Hospital neonatal intensive care unit. Study protocol and informed
consent documents were approved by the Loma Linda University Children's Hospital
Institutional Review Board. Subjects included in the study were premature infants ≤ 36.5
weeks' gestation who: (1) weighed ≥800 g; (2) had a central catheter in place; and (3)
required a heel lance. Exclusion criteria included neonates: (1) with unstable
oxygenation and hemodynamic status; (2) receiving opioids or sedatives or any
antiepileptic medications; (3) diagnosed with intraventricular hemorrhage ≥ grade 3; or
(4) with facial or multiple congenital anomalies that might alter the pain response. The
heel lance was performed for an accurate measurement of blood glucose from neonates
receiving glucose-rich total parenteral nutrition through a central catheter. Parents of
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premature infants who met study criteria were approached for informed consent as soon
after birth as possible. With consent, subjects were randomized into 1 of 3 groups: (1)
control; (2) placebo with non-nutritive sucking (NNS, or pacifier); or (3) sucrose (SweetEase; Children's Medical Ventures, Phillips Healthcare, Andover, Massachusetts) with
NNS (Figure 1). Randomization was performed by a research pharmacist, who used a
permuted block randomization table generated by the study statistician. The
experimental procedure is described in Figure 2. Investigators collaborated with the
clinical staff to obtain a sample of approximately 0.8 mL of blood from a central catheter
before (“0” minute) and 5 minutes after the heel lance to measure purine and allantoin
levels. In control neonates who did not receive a study drug or undergo a heel lance,
similar samples were collected at “0” and 5 minutes from baseline. The time period of 5
minutes after heel lance for blood sample collection was based on previous
investigations, which showed plasma levels of purines and organic hydroperoxides
significantly increasing 5 minutes after conditions such as incomplete ischemia [15].
These data were validated by unpublished preliminary studies in our laboratory, where
we found increases in plasma purines compared with baseline five minutes after heel
lance, and purine values that were less than baseline, 20-30 minutes after heel lance.
Blood samples were centrifuged within 5 minutes to separate the plasma which was then
stored at −80°C. All samples were analyzed within 1 week of acquisition.
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Eligible = 230

Consent Given =
151

*Not Sampled = 20

Heel Lance:
Placebo/NNS
N=45

Control
N=42

Heel Lance:
Sucrose/NNS
N=44

Figure 1. Enrollment Flow Chart. *Reasons why subjects were not sampled include: change
in acuity or failure to meet study criteria after consent was obtained (n = 9); central line will not
draw or lipids were being infused preventing sampling (n = 5); and line was discontinued before
sampling could be scheduled (n = 6).

One hour
of quiet
time

Baseline
PIPP,
purine, and
allantoin

Study
Drug
Given

After 2 min
Heel Lance
(Group 2 & 3)*
& PIPP

After 5 Min
purine and
allantoin

Figure 2. Study Procedure. *Control neonates received no study drug, no heel lance. PIPP and
plasma markers are obtained at baseline and five minutes after baseline.
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Heel Lance Procedure And Administration Of Study Drug
The study drug was prepared immediately before the experimental procedure by
the research pharmacist and labeled as “study drug” to ensure blinding. The dose of
sucrose was based on previously published studies in premature infants [12, 16-18].
Neonates randomized to the sucrose group received a single dose of 24% sucrose in the
following volumes: 2 mL for neonates >2 kg, 1.5 mL for neonates 1.5-2 kg, and 0.5 mL
for neonates that were <1.5 kg. The study drug was administered slowly via syringe to
the anterior tongue along with a pacifier (NNS) 2 minutes before the heel lance. Multiple
studies showed that sucrose was most effective when given approximately two minutes
before heel lance [8, 18-23]. Neonates randomized to the placebo group received an
equal volume of sterile water to the anterior portion of the tongue along with a pacifier.
The neonate's face was videotaped by trained research staff to record facial action at “0”
minutes, during the heel lance and up to 30 seconds post heel lance.

Pain Assessment
To assess pain, we used the PIPP, an instrument designed to assess acute pain in
preterm neonates [13]. This scoring system includes seven items, each graded from 0 to
3. Two items describe baseline characteristics of the neonate (gestational age and
behavioral state), 2 items are derived from physiologic measurements (heart rate and
oxygen saturation), and 3 items describe facial actions (brow bulge, eye squeeze, and
nasolabial furrow). Baseline pain was scored before the heel lance (0 minute) during a
30-second window. Procedural pain was scored from the time of heel lance to 30
seconds after the lance. Facial actions were recorded with a digital camera with real-time
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counter that allowed for intensive slow motion stop frame, videocoding, and playback.
Previous work on validation of the PIPP score showed an ability to differentiate painful
from non-painful or baseline events [13, 24].

Measurement Of Purines
Purine metabolites were measured as previously published by our laboratory [25].
Specifically, plasma was removed, transferred to separate Eppendorf tubes, and
immediately centrifuged in Eppendorf 5702R (Pittsburgh, Pennsylvania) centrifuge, for
30 minutes at 18000 g. The supernatant was transferred to Microcon centrifugal filter
devices (Millipore Corp, Bedford, Massachusetts), 200 μL per device, and spun for 90
minutes at 14000 g, 4°C. Filtrate was removed, and 150 μL was transferred to an
Eppendorf tube containing 1 × 10−7 mol of 2-aminopurine (internal standard). Highperformance liquid chromatography (Waters 996 PDA, 715 Ultra Wisp Sample
Processor; Millipore Corp) analysis was done in the same day, or the tubes were frozen at
−80°C until analysis. Previous analysis via high-performance liquid chromatography of
plasma demonstrated that purines remained stable with freezing.
Samples, 45-μL, were infected onto a Supelcosil LC-18-S 15 cm × 4.6 mm, 5-μm
column (SGE, Austin, Texas), with the following isocratic conditions: 50 mM
ammonium formate buffer, pH 5.5, flow rate 1.0 mL/min. Hypoxanthine, xanthine, and
uric acid were quantitated by obtaining peak areas at appropriate retention and
wavelengths [26]. Once the peak area of 2-aminopurine at approximately 10.8 minutes
and 305 nm was determined, the area ratios of hypoxanthine, xanthine, and uric acid to 2aminopurine were determined and converted to micromolar concentrations using standard
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curves. Samples were analyzed in triplicates and values with a coefficient of variation of
less than 10% were included in the final analyses. The limits of detection for the purines
are as follows: 1.58 μM hypoxanthine, 1.32 μM xanthine, and 5.0 μM uric acid.

Measurement of Allantoin
Allantoin was measured in plasma using an adaptation of the method developed
by Gruber et al [27] and Al-Khalaf and Reaveley [28]. Plasma (50 μL) was transferred to
an Eppendorf tube containing 5 × 10−10 mol internal standard (50 μL 10 μM [15N]-labeled
allantoin). Spiked samples were simultaneously deproteinized and extracted by the
addition of 100 μL of acetonitrile. Samples were then vortexed and centrifuged at 20000
g, 4°C for 5 minutes, and the supernatant was dried under N2. After drying, 50 μL of
MTBSTFA (N-methyl-N-tert-butyldimethylsilyltrifluoroacetamide) in pyridine (1:1
vol/vol) was added and the derivatization reaction was facilitated by incubation at 50°C
for 2 hours.
Analysis was performed on Agilent 6890N Network GC System connected to an
Agilent 5973 Inert Mass Selective Detector (both Agilent Technologies, Inc, Santa Clara,
California). Separation was performed using an Agilent 122-5532G capillary column
(25.7 m length, 0.25 mm internal diameter). Helium was used as the carrier gas at a flow
rate of 1.5 mL/min. Derivatized product (1 μL) was injected in split mode (split 20:1,
split flow 29.4 mL/min, total flow 33.8 mL/min). The initial column temperature was set
at 100°C and held at that temperature for 2 minutes, then increased to 180°C at a rate of
10°C/min. The column was held at this temperature for 4 minutes and then increased to
260°C at a rate of 20°C/min. This temperature was maintained until the end of the run.
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Allantoin was quantified using selected ion monitoring mode with the 398.00 m/z ion
being monitored for allantoin and the 400.00 m/z for DL-allantoin-5-13C;1-15N. The ion
abundance ratios (398.00/400.00) were converted to micromolar concentrations by use of
a standard curve.

Statistical Analyses
A repeated-measures ANOVA with one between factor (type of intervention) and
one within factor (time) was used to compute the minimum sample size needed for this
study. The sample size was based on the following assumptions: (1) the significance
level was set to 0.05; and (2) required power was 80%. After adjusting for a 10%
dropout rate, we enrolled 42-45 participants per group for a total of 131 subjects.
To analyze the data, assumptions of normality and equal variance were assessed.
Demographic data for categorical variables were analyzed by use of the χ2 test.
Repeated-measures ANOVA for one between subject factor (group) and one within
subject factor (time) were assessed to evaluate the effect of the heel lance on plasma
purines and allantoin concentrations over time. Interaction terms in the general linear
model were used for this purpose. The interaction terms assess the differences between
the groups over time. Correlations between purines, allantoin, and biobehavioral markers
(PIPP) were examined with the Spearman rho. All statistical analyses were performed
using SPSS Statistics for Windows Version 20 (SPSS Inc, Chicago, Illinois). Differences
were considered significant at P < .05.
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Results
General Results
Of the 151 subjects who provided consent between the months of July 2009 and
February 2012, 131 subjects were randomized into 1 of 3 groups: control (n = 42), heel
lance and placebo (n = 45), or heel lance and 24% sucrose (n = 44; Figure 1). All
subjects randomized to the heel lance groups were given a pacifier (NNS) immediately
before, during, and after study drug administration. There were no significant differences
between the groups (Table I).

Effects of Oral Sucrose on Behavioral and Physiological Markers of
Pain
There were no significant differences in baseline pain score between the 3 groups
(Table II). Sucrose significantly attenuated the increase in pain score in response to heel
lance, compared with placebo (Table II). The heart rate response to heel lance was
greatest in the sucrose group (P < .001). Heart rate increased by 11% in the sucrose
group, compared with 6% in the placebo group and 0.5% in the control group. We
observed no significant changes in mean oxygen saturation in response to heel lance.
These data suggest that the lower pain scores in the sucrose group were attributable to
significant reductions in the behavioral components of the PIPP scoring tool and not from
physiological markers of pain such as heart rate or oxygen saturation.

Effects of Oral Sucrose on Markers of ATP Metabolism (Purines) and
Oxidative Stress (Allantoin)
There were no significant differences in baseline purine and allantoin levels in
any of the groups. However, although plasma purine and allantoin concentration
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Table 1. Subject demographics. EGA, estimated gestational age; NCPAP, nasal continuous
positive airway pressure; NIPPV, noninvasive intermittent positive pressure ventilation; RA,
room air; SNAPPE-II, Score for Neonatal Acute Physiology−Perinatal Extension-II. *One-way
ANOVA.† χ2 test.
Control
(n = 42)
EGA, weeks
Birth weight, g
Apgar, 1 minute
Apgar, 5 minute
Sex, n (%)
Male
Female
Race, n (%)
White
Hispanic
African American
Asian
Other
Condition at time of
sampling
FiO2, %
EGA, weeks
SNAPPE-II

Heel lance,
Sweet-Ease/NNS
(n = 44)
30.1 ± 3.1
1374.1 ± 552
6±2
7±2

F value

P value

30.5 ± 2.6
1456.4 ± 502
5±3
7±2

Heel lance,
placebo-NNS
(n = 45)
30.3 ± 3.2
1498.4 ± 706
5±3
7±2

0.218*
0.499*
0.961*
1.008*

.804
.608
.385
.368

25 (60%)
17 (40%)

22 (49%)
23 (51%)

22 (50%)
22 (50%)

1.175†

.556

15 (36%)
15 (36%)
6 (14%)
2 (4%)
4 (10%)

14 (31%)
21 (47%)
7 (16%)
2 (4%)
1 (2%)

19 (43%)
15 (34%)
6 (14%)
2 (4.5%)
2 (4.5%)

4.277†

.831

0.25 ± 0.07

0.26 ± 0.09

0.23 ± 0.03

1.783*

.172

*

32.5 ± 2.3
7.8 ± 10.8

32.6 ± 2.6
7.9 ± 11.9

33.1 ± 2.1
8.3 ± 11.6

0.759
0.020*

.470
.980

19
6
6
11

19
11
6
0

24
11
1
8

6.861†

.334

Hemoglobin

13.1 ± 2.4

12.7 ± 2.3

12.5 ± 2.2

0.846*

.432

Hematocrit

38.7 ± 6.5

37.6 ± 6.4

36.9 ± 5.7

0.844*

.433

Mode of O2 delivery
Spontaneous RA
Nasal cannula
NCPAP
NIPPV
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Table 2. Pain score, heart rate, and oxygen saturation *One-way ANOVA. † Sweet-Ease
group significantly lower than control or placebo groups. ‡ Control group significantly lower than
both heel lance groups.

Pain score Mean
(min-max)
Baseline
Procedural
Heart rate
Baseline
Procedural
Oxygen saturation
Baseline
Procedural

Control (n = 42)

Heel lance,
placebo-NNS
(n = 45)

Heel lance, SweetEase/NNS (n = 44)

F value

P value

3.9 (1-8)

3.8 (1-8)

3.8 (1-7)

0.233*

.792

*

.003†
.814

5.9 (2-15)

6.3 (2-12)

4.6 (2-10)

6.216

154.4 (12.8)

155.9 (14.4)

154.1 (13.3)

0.206*
*

<.001‡

154.9 (13.9)

164.9 (14.6)

170.5 (14.7)

14.480

96.5 (0.5)

96.2 (0.5)

96.2 (0.5)

0.123*

.885

96.2 (0.6)

95.8 (0.6)

96.4 (0.6)

0.235*

.791
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decreased over time in subjects randomized to the control and placebo groups, we
observed a significant increase over time in plasma hypoxanthine and uric acid in
neonates who received sucrose before the heel lance (Figure 3A and B). This effect
persisted even when analysis was limited to subjects <33 weeks' gestation at the time of
sampling. Xanthine concentrations remained stable over time in each of the 3 groups.
Plasma allantoin concentration increased over time in those who received sucrose;
however, this effect was not statistically significant (data not shown).

Effects of Oral Sucrose on Plasma Allantoin in Neonates with a
Minimal Pain Response to Heel Lance
We found that 63% of neonates who received sucrose demonstrated a minimal
response to heel lance, defined as an increase in PIPP score of <33%. When we
examined the effect of sucrose in this subgroup, we found that plasma allantoin
concentration increased significantly over time (Figure 3C). When we examined the
correlation between the percent change in PIPP pain score over time and the percent
change in allantoin concentration over time, we found a significant negative correlation
(Spearman rho, −0.378, P = .014), suggesting that although sucrose significantly
decreased the pain scores, it also increased markers of oxidative stress in this subgroup of
premature neonates.
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Figure 3. Differences in Purine and Allantoin Concentrations 5 min post TDP. A and B,
Plasma hypoxanthine and uric acid concentration increased over time in preterm neonates who
received oral sucrose before a clinically required heel lance. C, In neonates with minimal pain
response (<33% increase in PIPP with heel lance), plasma allantoin concentration increased over
time.
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Discussion
Although oral sucrose given before a single heel lance significantly decreased
behavioral markers of pain, consistent with the findings of numerous clinical
investigators [8, 17, 23, 29], it also increased markers of ATP use, as evidenced by
significant increases over time in plasma hypoxanthine and uric acid concentrations. The
relationship between sucrose, ATP use/depletion, and increased purine production is well
documented in adult animal and human literature (Figure 4)[6, 30, 31]. Sucrose is a
disaccharide of glucose and fructose. It is hydrolyzed by sucrase, an enzyme secreted by
epithelial cells of the villi in the small intestine (Figure 4A). Both glucose and fructose
are rapidly absorbed from the gastrointestinal tract through glucose transporter GLUT5
(fructose) and sodium-glucose cotransporter/GLUT2 (glucose) transporters in the apical
membrane and transferred to the portal circulation via GLUT2 transporters in the
basolateral membrane of enterocytes (Figure 4B). The expression of these GLUTs is upregulated by exposure of intestinal lumen to fructose solutions [32] or by previous
exposure to corticosteroids [33]. Once in circulation, glucose uptake is insulin-dependent
while fructose uptake is independent of insulin [4]. Inside the cell, fructose is rapidly
phosphorylated to form fructose-1-phosphate by the enzyme fructokinase (Figure 4C).
The activity of fructokinase is 4-fold greater than glucokinase (the enzyme that
phosphorylates glucose). Moreover, fructokinase activity is relatively unregulated,
being limited only by fructose concentration [34]. Fructose-1-phosphate is split by
aldolase (aldolase B) into glyceraldehyde and dihydroxyacetone phosphate, a member of
the glycolysis sequence of intermediates. The third enzyme in the fructose pathway is
triokinase, which catalyzes the phosphorylation of glyceraldehyde to glyceraldehyde-3-
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Figure 4. Sucrose metabolism. A) Sucrose is hydrolyzed into fructose and glucose by the
enzyme sucrase. B) Glucose and fructose are absorbed from the gastrointestinal tract, transferred
to the portal circulation, and enter hepatocytes. C) Fructose is phosphorylated to form fructose-1phosphate by the enzyme fructokinase. D) Fructose phosphorylation rapidly depletes the cell of
ATP and inorganic phosphate. E) Decreases in ATP production, in addition to increased ATP
utilization, results in increased hypoxanthine, xanthine, and uric acid production. If this is
combined with increased oxidative stress, uric acid can be oxidized to form allantoin. SGLT,
sodium-glucose cotransporter; ISF, interstitial fluid; TCA, tricarboxylic acid cycle; IMP, inosine
monophosphate.
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phosphate, another intermediate in the glycolytic pathway.
These fructose-related biochemical reactions are significant because each
phosphorylation step requires ATP [31]. As ATP is consumed, it is degraded to ADP,
leading to an increase in ADP concentration [4]. Simultaneously, inorganic phosphate
levels decrease because they are sequestered in fructose-1-phosphate or the mitochondria
to generate ATP necessary to maintain fructose phosphorylation (Figure 4D) [4]. As
inorganic phosphate concentration decreases, oxidative phosphorylation is inhibited,
reducing ATP synthesis and rapidly depleting ATP [4, 6, 30, 31]. ATP and ADP
catabolism results in increased concentration of purines such as uric acid (Figure 4E) [5,
6, 35]. These observations have been documented in adult animals as well as in children
ages 11 months to 12 years [5] and in healthy adults [5, 6]. We show similar effects in
preterm neonates, in which a single dose of sucrose significantly increased plasma
hypoxanthine and uric acid concentrations.
We also found that neonates in the sucrose treatment group had the largest
increase in heart rate compared with those in the control or placebo groups, providing
additional evidence that sucrose does not attenuate the tachycardia that accompanies
painful procedures, but may increase it. This increase in heart rate may be due to the
stimulatory effect of sucrose on the sympathetic nervous system, as shown in rats [36, 37]
and healthy young adults [38]. Interestingly, in humans, the sympathetic response to
sucrose ingestion was enhanced under conditions of acute moderate hypoxia[39].
Together, these data suggest that the apparent analgesic effect of oral sucrose may come
at a price, namely tachycardia, which in turn contributes to increased ATP use.
An additional finding of this study is the effect of sucrose administration on
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plasma allantoin concentration in neonates with reduced pain responses (PIPP score
increased by <33%). We found that plasma allantoin increased over time when compared
to control and placebo groups; however, this increase was only significant when neonates
within the sucrose group who exhibited a larger pain response (defined as having an
increase in PIPP score of ≥34% compared with baseline) were escluded (Figure 3C).
The demographics of this subgroup of neonates were not significantly different from
those with a larger pain response. Although newborns with reduced pain responses had
significantly lower baseline heart rates (151 ± 11.6 beats/min vs 159 ± 14.4 beats/min,
P = .028), they tended to have a greater percent change in heart rate with the heel lance
procedure compared with those with larger pain responses (12 ± 7% vs 9 ± 7%, P = .290).
These data suggest that changes in heart rate due to sucrose administration may be more
predictive of oxidative stress than changes in facial or behavioral activity. Additional
studies are required to examine the relationship between sucrose administration, pain
reactivity, and oxidative stress.
A limitation of this study is that although statistical power of more than 80% was
achieved for hypoxanthine and uric acid, it was not achieved for allantoin. A larger
sample size may be required to adequately examine the effect of sucrose treatment on
allantoin. It is possible that a significant increase in allantoin may not be always evident
five minutes after the heel lance procedure.
In this prospective, randomized, double-blind study, we made the observation that
a single dose of oral sucrose, given before a heel lance, significantly increased markers of
ATP use and oxidative stress in premature neonates over time. This finding suggests that
the apparent analgesic effect of oral sucrose may come at a price, namely increased ATP
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use. Because neonates can be exposed to numerous painful procedures per day requiring
multiple doses of sucrose, randomized trials should be performed to examine the effects
of repeated sucrose administration not only on markers of ATP breakdown and oxidative
stress but also on cellular injury. If it is determined that the metabolic risks of using
sucrose in neonates is indeed greater than the known benefits of reducing behavioral
indices of pain, additional studies need to be performed to identify alternative effective
substances or methods to prevent or treat pain in neonates.
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Abstract
Before urine can be used to evaluate the biochemical consequences of pain on
adenosine triphosphate (ATP) utilization and oxidative stress, the clinical factors that
alter the urinary concentrations of markers of ATP breakdown and oxidative stress need
to be determined. Here we report the effects of gestational age, weight for gestational
age, and neonatal morbidity on urinary hypoxanthine, xanthine, uric acid, and allantoin.
Urine was collected from 294 premature infants born at <28weeks gestation
(n=47), 28-306/7 weeks gestation (n=21), 31-336/7 weeks gestation (n=67), and 34-366/7
weeks gestation (n=159). Of the infants born between 34-366/7 weeks gestation, 22
infants were small for gestational age (SGA), 125 infants were appropriate for gestational
age (AGA), and 12 infants were large for gestational age (LGA). The effect of neonatal
morbidity was also determined in the 34-366/7 weeks gestation, late preterm, cohort. The
most prevalent morbidities within this group were poor nippling (n=11), poor nippling
plus hyperbilirubinemia (n=24), poor nippling plus early respiratory disease (n=40), or
respiratory disease alone (n=32). HPLC and GCMS were used to evaluate the effects of
gestational age, weight for gestational age, and mild morbidity on urinary markers of
ATP utilization (hypoxanthine/creatinine, xanthine/creatinine, uric acid/creatinine) and
oxidative stress (allantoin/creatinine).
We found that infants born before 28 weeks estimated gestation age (EGA) had
significantly higher mean day of life 1-4 urinary uric acid compared to infants born
between 28-306/7 weeks EGA (P<0.001) as well as significantly higher urinary
hypoxanthine, xanthine, uric acid and allantoin compared to infants born between 31336/7 weeks EGA (P<0.001 for all markers) and infants born between 34-366/7 weeks
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gestation (P<0.001, P=0.002, P<0.001, and P<0.001 respectively). In the late preterm
cohort (34-366/7 weeks EGA) we found that SGA infants had significantly lower urinary
hypoxanthine compared to AGA (P=0.020) and LGA (P=0.026) infants. Also within this
population, we found that respiratory morbidity significantly altered urinary purine
concentrations. Infants diagnosed with respiratory disease alone had significantly higher
mean day of life 1-4 urinary hypoxanthine compared to infants diagnosed with poor
nippling alone (P=0.003), poor nippling plus hyperbilirubinemia (P<0.001), or poor
nippling plus early respiratory disease (P=0.003). In addition, infants with respiratory
disease had significantly higher xanthine compared to infants diagnosed with poor
nippling plus hyperbilirubinemia (P=0.001) as well as significantly higher uric acid
compared to infants with poor nippling alone (P=0.014). Allantoin, a marker of oxidative
stress, was only significantly altered by gestational age.
These data indicate that factors such as gestational age, weight for gestational age
and respiratory disease significantly alter markers of ATP breakdown and must be
accounted for when using purines or allantoin to evaluate the biochemical consequences
of pain.

Background
To examine the relationship between procedural pain and hypoxia in infants, our
laboratory measured and reported alterations in plasma markers of adenosine triphosphate
(ATP) utilization and oxidative stress in rabbit kits [1] and premature infants [2, 3]
exposed to tape removal or heel lance, two painful procedures commonly performed in
the neonatal intensive care unit (NICU). These studies required subjects to have a central
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arterial or venous catheter in order to obtain blood samples without causing additional
pain; however, many infants in the NICU do not have a central line or have their lines
discontinued soon after birth. Furthermore, these studies were limited to evaluating a
single painful procedure due to the limited blood volume of premature infants and to
reduce the risk of infection.
One possible solution to these problems is to utilize urinary biomarkers to identify
the effects of procedural pain on oxidative stress and ATP utilization in premature
infants. Urine provides a non-invasive means of measuring purines and allantoin;
however, these markers are not specific to pain. Purine degradation products are wellestablished markers of hypoxia [4-9]. When the supply of oxygen cannot meet tissue
demand, metabolism switches from aerobic to anaerobic and ATP is broken down to
generate energy [10]. The degradation of ATP results in elevated levels of adenosine
monophosphate and free adenosine, which are subsequently catabolized into inosine
monophosphate and inosine, respectively. Both inosine monophosphate and inosine are
then converted to hypoxanthine, then to xanthine, and finally to uric acid. Uric acid has
the ability to act as an antioxidant by scavenging reactive oxygen species which converts
the compound mainly to allantoin, a marker of oxidative stress in humans [11]. Research
indicates that allantoin is also elevated under conditions of ischemia-reperfusion and
inflammation [12, 13].
Because of the effects of tissue hypoxia on ATP metabolism, we examined
common neonatal conditions that may cause measurable changes in the urinary
concentrations of purines and allantoin. Several investigators have reported that both
gestational age and weight for gestational age affect neonatal mortality rates [14-16]. It
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has further been reported that the that fractional excretion of uric acid is inversely related
to gestational age [17]. Pulver et al. recently reported that even late preterm infants who
are born small for gestational age are 44 times more likely to die in the first month of life
and are 21 times more likely to die in the first year of life than appropriate weight for
gestational age term infants [14]. To the best of our knowledge, the effects of weight for
gestational age on purine and allantoin concentrations have not been reported in infants;
however, research indicates that elevated maternal uric acid concentrations is associated
with an increase rate of small for gestational age birth [18].
It is also known that neonatal morbidities associated with poor prognosis or major
neurological impairment (hypoxia-ischemia, asphyxia, intraventricular hemorrhage, and
periventricular leukomalacia) increase ATP breakdown [8, 19, 20]. The effect of more
mild morbidities (respiratory disease, hyperbilirubinemia, poor nippling) on oxidative
stress and ATP breakdown has not been well studied. Late preterm infants, infants born
between 34 and 366/7 weeks gestation, provide a unique population for studying the
effects of mild to moderate neonatal morbidity on ATP breakdown and oxidative stress.
This population has a higher incidence of morbidity than term infants, but have lower
incidence of morbidity than more premature infants [21-31]. The morbidities most
frequently experienced by late preterm infants tend to be milder and include temperature
instability, hypoglycemia, respiratory distress, hyperbilirubinemia, infection and feeding
difficulties [22-31]. Many of these morbidities can be linked to increases in oxygen
demand, metabolism, energy utilization, and oxidative stress (Figure 1). In addition,
these infants are less likely to have central lines than more premature infants and may
benefit most from urinary analysis of purines and allantoin. The goal of this study was to
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determine the effect of gestational age, weight for gestational age, and mild/moderate
neonatal morbidity on the urinary concentrations of purines and allantoin in premature
infants. Late preterm infants were chosen to evaluate the effects of mild/moderate
morbidity for several reasons. First, this population is less likely to have central lines
when compared to more premature infants. Second, research has already established the
effects of severe morbidity on purine concentrations; however, the effects of clinically
mild to moderate morbidities on the urinary concentrations of purines and allantoin is
unknown. Third, the late preterm population is understudied and often clinically
managed as if they were term. Lastly, because we hypothesized that urinary purine and
allantoin excretions will be inversely related to gestational age, we wanted to control for
gestation in our morbidity studies. These studies reveal that gestational age, weight for
gestational age, and morbidity alter the urinary excretion of purines and allantoin and
need to be accounted for if these compounds are to be utilized to evaluate the metabolic
consequences of pain in premature infants.
The goal of this study was to determine the effect of gestational age, weight for
gestational age, and mild/moderate neonatal morbidity on the urinary concentrations of
purines and allantoin in premature infants. Late preterm infants were chosen to evaluate
the effects of mild/moderate morbidity for several reasons. First, this population is less
likely to have central lines when compared to more premature infants. Second, research
has already established the effects of severe morbidity on purine concentrations;
however, the effects of clinically mild to moderate morbidities on the urinary
concentrations of purines and allantoin is unknown. Third, the late preterm population is
understudied and often clinically managed as if they were term. Lastly, because we
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hypothesized that urinary purine and allantoin excretions will be inversely related to
gestational age, we wanted to control for gestation in our morbidity studies. These
studies reveal that gestational age, weight for gestational age, and morbidity alter the
urinary excretion of purines and allantoin and need to be accounted for if these
compounds are to be utilized to evaluate the metabolic consequences of pain in premature
infants.

Methods
Subject Enrolment And Sample Collection
Premature neonates admitted to Loma Linda University Children’s Hospital
neonatal intensive care unit were included in this study. The Loma Linda University
Institutional Review Board approved study protocol and informed consent documents.
No infants were excluded from the study; however, major anomalies, severe morbidity,
and comorbidities were noted. Weight for age and morbidity studies were carried out in
late preterm infants. Primary and secondary diagnosis was determined by a
neonatologist.
After parental consent was obtained, investigators collaborated with the clinical
staff to obtain urine samples. Urine was collected in 12-hour aliquots over the first seven
days of life by placing cotton balls over the urethral meatus. Urine-soaked cotton balls
were removed with every diaper change and stored at 0oC. Validation studies performed
in our laboratory showed that purines, creatinine, and allantoin concentrations remained
stable under our sampling and processing conditions. Urine was extracted from the
cotton using pressure, centrifuged for 10 min at 20000xg and 4oC, filtered through a
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Millex syringe driven filter (Low Protein Binding Durapore PVD filter, 0.45um, 13mm;
Millipore Corp.), and stored at -80oC until analysis.

Subject Classification
Infants with birth weights in the lower 10% or upper 90% of the weight for age
growth chars were classified as small and large for gestational age respectively.
Neonates with poor nippling are those with oral motor immaturity without signs and
symptoms of feeding intolerance or necrotizing enterocolitis. Neonates with poor
nippling plus hyperbilirubinemia are those with oral motor immaturity who received
phototherapy at some point over the first six days of life. Neonates with poor nippling
plus initial respiratory disease are those with oral motor immaturity and evidence of
apnea or ventilatory support for three days or less. Neonates with with respiratory
disease alone are those with transient tachypnea of the newborn (TTNB) or radiographic
evidence of respiratory distress syndrome (RDS) or pneumonia requiring oxygen and/or
ventilatory support over at least a successive four-day period in the first six days of life.

Purine And Creatinine Quantification
Urinary purine and creatinine concentrations were determined using an adaptation
of the HPLC method described by George et al [32]. Briefly, urine samples were thawed
and sonicated before 200 µl was transferred to an Eppendorf tube containing 1 x 10-7 mol
of 2-aminopurine (internal standard). The samples were then analyzed on an HPLC
(Waters 996 PDA, Waters 600 controller, and 717 plus autosampler; Millipore Corp) by
injecting 35 µl onto a Supelcosil LC-18-S 15 cm x 4.6 mm, 5 µm column (SGE; Austin,
TX), with the following isocratic conditions: 10 mM potassium dihydrogen phosphate
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buffer, pH 4.7, flow rate 1.0 ml/min. Creatinine, hypoxanthine, xanthine and uric acid
were quantitated by obtaining peak areas at the appropriate retention times (~3.5, 8, 9.5,
and 6.5 min respectively) and wavelengths (230, 248, 267, and 288nm respectively). The
area ratios of each compound to 2-aminopurine (13.5 min and 305 nm) were determined
and converted into micromolar concentration using standard curves. Samples were
analyzed in triplicate and values with a coefficient of variation less than 10% were
included in the final analysis. The limits of detection for the purines and creatinine are as
follows: 1.58 µM hypoxanthine, 1.32 µM xanthine, 5.0 µM uric acid, and 3.2 µM
creatinine.

Allantoin Quantification
Urinary allantoin concentrations were determined using an adaptation of the gas
chromatography mass spectrometry method described by Gruber et al[33]. Briefly, urine
samples were thawed and sonicated before 25 µl was transferred to an Eppendorf tube
containing 5x10-10 mol of internal standard (50µl of 10µM solution of 15N-labeled
allantoin). Spiked samples were deproteinated and extracted with 100 ml of acetonitrile.
Samples were then vortexed, centrifuged at 4oC for 5 minutes at 20000 x g, and the
supernatants were dried under N2. After drying, 50 µl of MTBSTFA in pyridine (1:1
vol/vol) was added and the derivatization reaction was facilitated by incubation at 50oC
for 2 h.
Analysis was performed on an Agilent 6890N Network GC System connected to
an Agilent 5973 Inert Mass Selective Detector. Separation was performed on an Agilent
122-5532G capillary column (25.7m length, 0.25mm internal diameter) with helium, at a
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flow rate of 1.5mL/min, as the carrier gas. Allantoin was quantified using selected ion
monitoring mode with the 398.00m/z ion being monitored for allantoin and the
400.00m/z for DL-Allantoin-5-12C;1-15N. The ion abundance ratios were converted to
micromolar concentration units by use of a standard curve. All measurements were
performed in triplicate. Values with a coefficient of variation of less than 10% were
included in the final analyses.

Stability Of Purines, Allantoin And Creatinine
To determine the stability of hypoxanthine, xanthine, uric acid, allantoin, and
creatinine over time and at varying temperatures, urine samples were collected from
volunteers the compounds were measured by HPLC or GCMS. Samples were subjected
to the fallowing conditions: direct analysis, immediate cotton extraction and analysis, or
incubation at room temperature (3 hours, 24 hours, 3 days, and 1 week), 36oC (3 hours or
6 hours), 0oC (24 hours or 1 week), or -80oC (24 hours or 1 week). Purines and
creatinine as well as the ratio of each to creatinine were found to be stable under all
conditions tested with coefficient of variation between the mean concentrations for each
processing condition being within 10% of fresh urine. Allantoin, on the other hand,
significantly increased in concentration when left at room temperature for 24 hours but
remained stable when incubated at 36oC for 6 hours or stored at temperatures of 0oC and
lower.

Statistics
To analyze the data, assumptions of normality and equal variance were assessed.
Demographic data for categorical variables were analyzed using Chi-square test. One-
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way ANOVA was used to evaluate the effects of gestational age, weight for gestational
age, and morbidity on mean DOL 1-4 urinary purines and allantoin. All statistical
analyses were performed using SPSS Statistics for Mac OS Version 21. Differences were
considered significant at P < 0.05.

Results
General Results
Urine was collected from 294 premature infants born at <28weeks gestation
(n=47), 28-306/7 weeks gestation (n=21), 31-336/7 weeks gestation (n=67), and 34-366/7
weeks gestation (n=159). As expected, significant differences were observed between
gestational age groups for 1-min Apgar, 5-min Apgar, and birth weight (Table 1). There
was also a trend for more males in each group except for the poor nippling plus
hyperbilirubinemia group. Of the infants born between 34-366/7 weeks gestation, 22
infants were SGA, 125 infants were AGA, and 12 infants were LGA. No significant
differences were found between these groups; however, LGA infants tended to have
lower Apgar scores and a large majority were born via cesarean section (Table 2).

152

Table 1: Subject Demographics for Gestational Age Groups. SVD: Spontaneous vaginal
delivery; C/S: Cesarean Section; Data are Mean ± SD; *One-way ANOVA, †Chi-square test
‡<28 and 28-306/7 significantly different from 31-336/7 and 34-366/7. <28 and 28-306/7
significantly different from all other groups. All groups are significantly different from one
another.
<28
(n=47)

28-306/7
(n=21)

31-336/7
(n=67)

34-366/7
(n=159)

P value*

Apgar, 1 min

4±3

5±2

7±2

7±2

0.000‡

Apgar, 5 min

6±2

7±2

8±1

8±2

0.000

829.5 ±
187.4

1150.6 ±
275.5

1875.4 ±
308.1

2325.0 ±
493.3

0.000

32
(68.1%)

6
(8.6%)

37
(55.2%)

83
(52.2%)

0.024†

15
(31.9%)

15
(71.4%)

30
(44.8%)

76
(47.8%)

15
(31.9%)
32
(68.1%)

5
(23.8%)
16
(76.2%)

22
(32.8%)
45
(67.2%)

63
(39.6%)
96
(60.4%)

NS
(0.409)†

44
(93.6%)
1
(2.1%)
2
(4.3%)

16
(76.2%)
3
(14.3%)
2
(9.5%)

58
(86.6%)
8
(11.9%)
1
(1.5%)

125
(78.6%)
22
(13.8%)
13
(7.5%)

NS
(0.153)†

Birth Weight (g)
Gender, n (%)
Male
Female
Mode of Birth, n (%)
SVD
C/S
Weight for age, n (%)
AGA
SGA
LGA

153

Table 2: Subject Demographics for Weight for Gestational Age Groups. EGA: estimated
gestational age; SVD: Spontaneous vaginal delivery; C/S: Cesarean Section; Data are Mean ±
SD; *One-way ANOVA, †Chi-square test

Apgar, 1 min
APGAR, 5 min
EGA (weeks)
Gender, n (%)
Male
Female

SGA
(n=22)
7±2

AGA
(n=125)
7±2

LGA
(n=12)
5±3

NS (0.141)

8±1

8±1

7±2

NS (0.058)

35 ± 0.8

35 ± 0.8

35 ± 0.8

65
(52.0%)

6
(50.0%)

60
(48.0%)

6
(50.0%)

54
(43.2%)
71
(56.8%)

1
(8.3%)
11
(91.7%)

12
(54.5%)
10
(45.5%)

P value*

NS (0.325)

NS (0.964)†

Mode of Birth, n (%)
SVD
C/S

8
(36.4%)
14
(63.6%)
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NS (0.059)†

Table 3: Subject Demographics for Late Preterm Morbidity Groups. EGA: estimated
gestational age; SVD: Spontaneous vaginal delivery; C/S: Cesarean Section; Data are Mean ±
SD; *One-way ANOVA; †Chi-square test. ‡All groups significantly different than Respiratory
Disease. Poor nippling plus Hyperbilirubinemia significantly different from Poor nippling plus
Mild Respiratory Disease and Respiratory Disease alone. +Respiratory disease significantly
different from Poor nippling plus Hyperbilirubinemia and Poor nippling plus Mild Respiratory
Disease
Poor
Nippling
(n=11)

Poor Nippling plus
Hyperbilirubinemia
(n=24)

Poor Nippling plus
Early Respiratory
Disease
(n=40)

Respiratory
Disease
(n=32)

P value*

Apgar, 1 min

7±2

7±2

7±2

6±3

NS (0.393)

Apgar, 5 min

9±1

9 ± 21

8±1

7±2

0.000‡

EGA (weeks)

35 ± 0.7

34 ± 0.4

35 ± 0.7

35 ± 0.7

0.001

Birth Weight
(g)

2251.7 ±
721.8

2108.8 ±
455.2

2294.5 ±
387.9

2593.1 ±
463.1

0.002+

8
(72.7%)
3
(27.3%)

14
(58.3%)
10
(41.7%)

20
(50.0%)
20
(50.0%)

15
(46.9%)
17
(53.1%)

NS
(0.454)†

5
(45.5%)
6
(54.5%)

17
(70.8%)
7
(29.2%)

18
(46.2%)
21
(53.8%)

9
(28.1%)
23
(71.9%)

0.018†

8
(72.7%)
2
(18.2%)
1
(9.1%)

19
(79.2%)
4
(16.7%)
1
(4.2%)

33
(82.5%)
6
(15.0%)
1
(2.5%)

24
(75.0%)
2
(6.3%)
6
(18.8%)

NS
(0.107)†

Gender, n (%)
Male
Female

Mode of Birth,
n (%)
SVD
C/S

Weight for
age, n (%)
AGA
SGA
LGA
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The effect of neonatal morbidity was determined in the late preterm, 34-366/7 weeks
gestation, cohort. The most prevalent morbidities within this group were poor nippling
(n=11), poor nippling plus hyperbilirubinemia (n=24), poor nippling plus early
respiratory disease (n-40), or respiratory disease alone (n=32). Significant differences
were observed between morbidity groups for 5-min Apgar (P<0.001), gestational age
(P=0.001), and birth weigh (P=0.002, Table 3). We also noted that more infants in the
poor nippling plus hyperbilirubinemia group were born via spontaneous vaginal
deliveries versus cesarean section.

Effect Of Gestational Age On Purine Catabolites And Allantoin
There was a trend for infants of lower gestation to have higher purines and
allantoin (Figure 2). Specifically, infants born at < 28 weeks gestation had significantly
higher mean day of life 1-4 urinary uric acid (P<0.001) and allantoin (P=0.043) compared
to infants born between 28-306/7 weeks gestation. Similarly, infants born at <28 weeks
gestation also had significantly higher hypoxanthine, xanthine, uric acid and allantoin
compared to infants born between 31-336/7 weeks gestation (P<0.001 for all markers) and
infants born between 34-366/7 weeks gestation (P<0.001, P=0.002, P<0.001, and P<0.001
respectively). In addition, infants born between 28-306/7 weeks gestation had
significantly higher hypoxanthine, uric acid, and allantoin compared to infants born
between 31-336/7 weeks gestation (P=0.030, P=0.001, P<0.001 respectively) and infants
born between 34-366/7 weeks gestation (P=0.033, P<0.001, and P<0.001 respectively).
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A

B

Hypoxanthine/Creatinine

0.040

0.014

0.035

0.012

†

0.030

†

Xanthine/Creatinine
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Effect Of Weight For Gestational Age On Urinary Excretion Of Purines And Allantoin
After controlling for gestational age by selecting for infants between 34-366/7
weeks gestation we found that SGA infants had significantly lower hypoxanthine
compared to AGA (P=0.020) and LGA (P=0.037) infants (Figure 3A). No significant
differences were found between weight for gestational groups for xanthine, uric acid, or
allantoin (Figure 3B-D).

Effect Of Morbidity On Purines And Allantoin In Late Preterm Infants
Infants diagnosed as having respiratory disease alone had significantly higher
hypoxanthine than infants diagnosed with poor nippling alone (P=0.003), poor nippling
plus hyperbilirubinemia (P<0.001), or poor nippling plus early respiratory disease
(P=0.003, Figure 4A). Xanthine was found to be significantly lower in infants diagnosed
with poor nippling plus hyperbilirubinemia (P=0.001) compared to infants diagnosed
with respiratory disease alone (Figure 4B). Infants diagnosed with poor nippling alone
had significantly lower uric acid (P=0.014) compared to infants diagnosed with
respiratory disease alone (Figure 4C). Urinary allantoin was not significantly different
between any of the groups (Figure 4D).

Discussion
The aim of this study was to examine the effects of gestational age, weight for gestational
age, and mild morbidity on the urinary concentration of purines and allantoin. We found
that gestational age significantly altered the urinary concentrations of purines and
allantoin. Weight for gestational age also altered the urinary concentration of purines and
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allantoin; however, the changes were only significant for hypoxanthine. In addition,
neonatal morbidity significantly changed urinary purines in that infants diagnosed with
respiratory disease alone had the highest concentration for all purines.
Previous studies have demonstrated an inverse relationship between gestational age and
uric acid [17]. Our data provide additional support for higher urinary purine
concentration in infants at the lowest gestational age groups, until roughly 31 weeks
gestation. In addition, we also report significantly higher allantoin, a marker of
inflammation and oxidative stress, in more premature infants. The observed increase in
urinary purine and allantoin concentrations could be caused by increased purine and
allantoin production and/or increased renal clearance. It is known that infants excrete
substantially greater quantities of uric acid per unit of body weight than adults or older
children [17, 34, 35]. Stapleton et al. reported that fractional excretion of uric acid was
nearly 70% for infants born between 29-31 weeks gestation and decreased to roughly
40% for infants born between 38-40 weeks gestation [17]. Increased urinary purine
concentrations were also shown to be a result of clinical conditions associated with
hypoxia or perinatal asphyxia [19, 36, 37]. Our data provide additional support that uric
acid is easily filtered and excreted and can be altered by prematurity and conditions that
increase ATP utilization. The mechanism for urinary excretion of allantoin is not well
studied; however, it was demonstrated that elevated urinary allantoin concentration were
associated with increased oxidative stress in adults exposed to continuous exercise or
therapies that increase synthesis of free radicals [38, 39], establishing this compound as
an important free radical marker in urine.
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To the best of our knowledge, we are the first to report the effects of weight for
gestational age on urinary purine and allantoin concentrations in late preterm infants.
Surprisingly, we found that SGA infants tended to have lower urinary purine
concentrations than AGA or LGA infants; with SGA infants having significantly lower
hypoxanthine than both AGA and LGA infants. This trend continued, but was not
significant, after controlling for neonatal co-morbidities (data not shown). The
mechanism for this reduction in urinary purines in SGA infants is unclear but could be a
result of increased purine salvage, decreased energy use/purine production, or decreased
renal clearance. However, an increase in purine salvage is unlikely because
hypoxanthine-guanine phosphoribosyltransferase (HGPRT) activity was shown to be
depressed in cord blood lymphocyte from SGA infants when compared to term infants
[40]. Furthermore, this is not likely a result of an overall reduction in purine metabolism
because this same study found similar adenosine deaminase activity between premature
SGA infants and term infants. This study, however, compared preterm SGA infants to
term infants. The HGPRT activity for SGA infants needs to be compared to age matched
AGA infants for purine salvage to be ruled out as an explanation for the decreased
urinary purine concentrations observed in our study.
It was further reported that SGA infants have similar metabolic parameters and
higher resting energy expenditure than age matched AGA infants in the first week of life;
indicating that the observed decrease in urinary purines in SGA infants may be due to
decreased excretion rather than decreased production [41]. Wang et al. reported higher
insulin levels in SGA infants compared to age matched AGA infants at 72 hours of
life[42]. Research indicates that hyperinsulinemia decreases uric acid excretion without
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significantly altering plasma uric acid concentration in adults [43]. Bauer et al., however,
have reported similar blood insulin levels between SGA and AGA infants [41]. Studies
investigating the mechanism of decreased urinary purine excretion in SGA infants need
to be conducted. Based upon these studies, as well as the data presented in the paper, it is
important to control for, or exclude, SGA infants from studies that use urinary purines as
markers of ATP breakdown.
We also found that respiratory morbidity within the late preterm population can
significantly alter urinary purines, but not allantoin. This was most evident for urinary
hypoxanthine. The elevated urinary purine concentrations in infant with respiratory
disease could be caused by decreased ATP production or increased ATP utilization. It is
well documented that hypoxia and asphyxia resulted in increased purine levels [5-9, 44].
In addition, it has been reported that plasma uric acid positively correlated with fraction
of inspired oxygen (FiO2) in intubated premature infants [45]. In this study, FiO2 was
adjusted per patient need. In our study, all of the infants in the respiratory morbidity
group were receiving oxygen and/or ventilatory support, indicating a need for
supplemental oxygen or assisted breathing and an increased purine production. It has
also been reported that respiratory morbidity can increase energy expenditure in
premature infants [46, 47]. The increase in purines observed in our study could be a
result of increased ATP utilization due to increased energy expenditure. It is well
documented that increases in energy expenditure result in increased purine production
[48, 49]. Our data indicate that infants with respiratory morbidities need to be grouped
separately from infants without respiratory morbidities if urinary purines are to be used to
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measure the relationship between procedural pain and hypoxia on ATP breakdown in
urine.
These data suggest that gestational age, weight for gestational age, and neonatal
morbidity alter the urinary concentration of purine metabolites. Allantoin was also found
to be significantly altered by gestational age. Based upon these data, we recommend
conducting age-matched as well as weight for age-matched studies when using urinary
purines and allantoin to evaluate the relationship between procedural pain and hypoxia on
ATP utilization and oxidative stress. Lastly, it is important to stratify subjects based on
health status or morbidity, due to the significant effects of neonatal respiratory diseases
on ATP use and oxidative stress.
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